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Abstract 
Engineered protein ligands have been successfully applied as molecular targeting agents in 
the clinic for diagnostic and therapeutic applications. Yeast surface display selections have shown 
effectiveness in discovery and evolution of ligands against a variety of target molecules to meet 
these ends. Often, these biomarkers are transmembrane proteins, which are made up with 
hydrophilic extracellular and intracellular domains and hydrophobic transmembrane domains. Due 
to these hydrophobic domains, full length transmembrane proteins are difficult to work with in 
aqueous systems. Thus, ligand selections are conventionally carried out against recombinant 
extracellular domains of these biomarkers. These molecules may be poor models of the 
corresponding full length, membrane associated proteins due to instability in the absence of the 
truncated domains, inadequacies in protein folding and post-translational modification, presence 
of non-natural tags required for protein purification and immobilization for selection, or 
denaturation during a variety of handling steps. Thus, ligand selection campaigns against these 
molecules often end with the evolution of ligands that bind the soluble target, but have diminished 
or abolished activity against the true biomarker of interest. The work presented here aims to 
provide a new toolkit for ligand selection that bypasses this translational hurdle by optimizing 
selections of yeast surface display libraries directly against target-expressing mammalian cell 
monolayers. Target specific binder enrichment is rigorously optimized and substantially improved 
through the use of a longer flexible linker in yeast surface display which enhances the recovery of 
even micromolar binding interactions that enable naïve library selections. Five ligand selection 
strategies using soluble target and cellular selection strategies are probed using a fibronectin 
domain and an affibody library, showing that methods partially or completely utilizing cellular 
selection strategies have a higher likelihood of isolating translatable binders while also developing 
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new ligands that bind tumor vasculature targets CD276 and Thy1. Controlled valency reduction 
using the reducing agent dithiothreitol (DTT) to reduce yeast-displayed ligand levels to 3,000-
6,000 ligands per cell enhances affinity discrimination between a 2 nM and 17 nM binder 16-fold, 
yielding a modular method for affinity-based cellular selection. This method is applied to 
discovery and affinity maturation of fibronectin domains targeting epithelial cell adhesion 
molecule (EpCAM) for oncological applications. Depletion of non-specific binding ligands is 
achieved using a pre-blocking strategy with disadhered mammalian cells, yielding a 14-fold 
selectivity advantage for a specific binder relative to a non-specific binder. Collectively, the results 
presented in this dissertation elucidate the factors that dictate cell-cell interactions within the 
context of yeast display ligand selections on mammalian cell targets and provide a suite of tools 
for ligand selections as well as a variety of targeting molecules with diagnostic and therapeutic 
applications. 
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Chapter 1 – Introduction 
1.1. Genotype-Phenotype Linkage for Protein Selection 
Engineered proteins with potent, specific binding activity are heavily used in the medical 
field for both diagnostic and therapeutic benefit. The ability to selectively recognize a molecule 
indicative of a disease state makes these engineered ligands strong candidates for in vivo 
diagnostics, such as targeted molecular imaging for patient stratification and treatment 
monitoring1, ex vivo analysis of blood and urine2–4, and targeted therapy through inhibition, drug 
delivery, radioisotope delivery, and immune system engagement5. Advances in proteomics and 
genomics have broadened the landscape of clinically relevant biomarkers6, leading to increased 
demand for new engineered ligands that target them. To meet this demand, several high-throughput 
screening strategies for binding activity have been employed. 
At the heart of high-throughput protein screening is the selection of a genotype-phenotype 
linkage strategy. This involves the expression of a ligand on the surface of an entity that contains 
the DNA sequence encoding for the expressed protein. Millions to billions of proteins can be 
screened for the desired binding activity with facile identification of the successful candidate by 
sequencing the tethered encoding gene. Common genotype-phenotype linkage strategies include 
phage display, ribosome and mRNA display, mammalian cell display, and yeast surface display 
(Figure 1-1). Phage display7–9 involves the fusion of a protein of interest to a coat protein 
bacteriophage, most commonly minor coat protein pIII or major coat protein pVIII. The 
bacteriophage itself contains single stranded DNA that encodes the protein of interest. Phage 
display has proven quite modular with the ability to display several protein scaffolds10–13, but 
displayed proteins are restricted to clones that can be produced and fold in the bacterial periplasm. 
Phage libraries of up to 1012 members can be built and efficiently screened9. Ribosome display14–
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16 and mRNA display17–19 constitute the two primary in vitro genotype-phenotype linkage 
strategies. In both methods, the genotype is provided by mRNA that has the encoded protein fused 
to it during translation. These methods currently have the largest library size (up to 1014 
members15) because they are not limited by the transformation efficiency of cells. These methods 
have been used to screen peptides20, antibody fragments21, DARPins22, and enzymes23. 
Mammalian cell display24,25 displays proteins of interest as fusions to the transmembrane domain 
of platelet derived growth factor receptor on HEK293T cells that contain the plasmid encoding the 
fusion. This method was developed for antibody fragment screening, citing that selection of 
antibodies in a human system yields clones that not only recognize antigen well, but also have 
favorable properties for mammalian production25. Library sizes using this method are quite small 
(103-106 clones), but can theoretically reach 109 clones24. 
In yeast surface display 26–28, Saccharomyces cerevisiae are transformed with plasmids that 
individually encode for a protein of interest fused to yeast mating protein agglutinin 2. Other fusion 
partners have also been used29. Upon induction of protein expression, the yeast produce and secrete 
the protein of interest, which becomes immobilized on the cell surface by the formation a pair of 
disulfide bonds between yeast mating protein agglutinin 1 and the fused agglutinin 2 (Figure 1-1). 
As there are thousands of agglutinin 1 on the surface of each yeast cell, thousands to tens of 
thousands of an individual protein of interest will be tethered to the yeast surface. This large 
quantity of ligands per yeast cell can provide avidity30, or strength of multiple interactions, in 
binding-based selection experiments, allowing ligands with very weak but evolvable affinity to be 
recovered, an advantage not shared by monovalent selection techniques. Yeast surface display also 
has the advantage of eukaryotic cellular machinery, which aids protein folding and allows the 
application of posttranslational modification26. It has been shown that this eukaryotic machinery 
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contributed to the discovery of many unique antibody fragments against HIV-1 gp120 when the 
same immune antibody library was screened in yeast surface display and phage display, a method 
dependent on the prokaryotic machinery of E. coli31. However, yeast surface display does suffer 
from the disadvantage of smaller library sizes than phage, mRNA, or ribosome display due to its 
transformation efficiency. Recent innovation in yeast transformation yields protein libraries with 
order 109 members32, improving the sequence space that yeast surface display libraries can sample 
relative to earlier iterations. 
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Figure 1-1. Schematic of genotype-phenotype linkage strategies and the yeast surface display 
construct. Several genotype-phenotype linkage strategies are commonly employed for 
protein screening. Here, each system is shown to relative scale with ligands (green circles) 
three times their actual size and plasmids (red circles) twice their actual size for visualization 
purposes. Yeast and bacteria contain plasmids encoding for the protein of interest. Phage 
contain single stranded plasmids encoding for the protein of interest. Ribosome display and 
mRNA display keep the mRNA that encodes the protein of interest tethered to the overall 
construct. In yeast surface display, the protein of interest is tethered to the yeast cell by a 
pair of disulfide bonds between cell wall anchored Aga1p and Aga2p, which is produced as 
a fusion to the desired ligand (shown here as a fibronectin domain). Figure reproduced with 
permission33. 
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1.2. Protein Selection with Recombinant Domains 
Most common protein selection strategies involve the use of recombinant extracellular 
domains of a biomarker of interest as the target. The extracellular domain of a transmembrane 
protein is generally easier to work with in an aqueous system than a full transmembrane protein 
due to the absence of the hydrophobic transmembrane domain. Recombinant extracellular domains 
can be produced in a wide range of host organisms, including bacteria, yeasts, mammalian cells, 
insect cells, and plant cells, though some of these hosts yield variability in post-translational 
modification and general quality relative to the native host 34. Once purified, the protein of interest 
is often conjugated with a tag, most commonly biotin, to aid selection. 
Selections using proteins immobilized on ELISA plates are often employed for isolating 
ligands from phage display, mRNA display, and ribosome display libraries9,15,18 (Figure 1-2A). 
Target proteins are immobilized either directly on the ELISA plate by adsorption (direct 
immobilization) or conjugated to biotin and bound to streptavidin that is immobilized to the ELISA 
plate (indirect immobilization). Both modes of immobilization have disadvantages. Direct 
immobilization yields target proteins that are immobilized in random orientations, hiding epitopes 
that face the plate from selection. Indirect immobilization requires the use of a chemical tag, 
potentially masking epitopes near the site of conjugation and introducing non-natural epitopes to 
the target protein. Display libraries are then introduced to the immobilized target protein, and 
ligands with affinity for the target will bind. Non-binding ligands are washed away, while bound 
ligands are recovered and propagated for the next round of selection. While this method succeeds 
for smaller entities, it is not suitable for selection of yeast displayed libraries30. 
Magnetic bead selections have been successfully employed for ligand selection from phage 
display and yeast surface display libraries30,35 (Figure 1-2B). This method can be divided into two 
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different techniques: selections against target-coated magnetic beads and selections against free 
target with magnetic bead capture. Selections against target-coated magnetic beads involve 
immobilization of target to magnetic beads by way of an affinity tag. After washing away free 
target, the beads are exposed to a ligand library, during which selection occurs. Due to the size and 
number of binding sites available per bead (e.g. 5 million per 3 µm streptavidin-coated 
Dynabead27), this method allows for the recovery of even weak binding interactions due to avidity 
in yeast surface display systems. In contrast, selections against free target with magnetic bead 
capture are carried out by introducing free target to a ligand library, allowing binding to occur, and 
then introducing magnetic beads to the system. The affinity tag on the target will bind the beads 
and allow for the recovery of bound ligands. This method allows for more affinity discrimination 
than selections against target coated magnetic beads because the initial binding interactions do not 
allow for avidity provided that the target is monovalent. However, weak avidity can allow for the 
recovery of some lower affinity binders that retain a sufficient number of targets once the magnetic 
beads are introduced to the system. 
Fluorescence-activated cell sorting is a powerful selection technique used for selecting 
ligands from yeast surface display and mammalian cell display libraries25,36 (Figure 1-2C). In this 
method, ligand libraries are incubated simultaneously with free fluorescent-tagged target and a 
fluorescent antibody to quantify ligand expression on the cell surface. After washing away 
unbound target, cells are analyzed using a flow cytometer, which is capable of detecting 
fluorescence associated with both ligand expression and binding simultaneously. Individual cells 
with the appropriate ligand expression : target binding ratio can be collected very precisely by 
gating fluorescent events with the desired binding activity. This method allows for fine affinity 
discrimination as target binding is monovalent, target concentration can be easily modulated, and 
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weakly binding clones don’t need to be collected36. However, the fluidics of flow cytometers can 
be harmful to mammalian cells due to shear stresses37. 
 
Figure 1-2. Schematic of ligand selection techniques. Ligands can be selected through a 
variety of techniques. Immobilization of soluble target in ELISA plate wells allows for 
selection of small entities, such as bacteriophage (A). Coating magnetic beads with soluble 
target allows high-throughput screening of yeast-displayed ligands through avid interaction 
(B). Monovalent interaction of yeast displayed ligands can be sorted through fluorescence-
activated cell sorting with soluble target (C). Yeast displayed ligands can also be sorted 
against target-expressing mammalian cell monolayers (D). 
1.3. Shortcomings of Soluble Extracellular Domains 
Soluble extracellular domains have been used as targets to generate ligands with activity 
against cell-expressed, full length receptors using several protein scaffolds11,22,38–42. Despite this, 
many ligand selection campaigns fail due to the inability of isolated ligands to bind full length 
target as expressed by intact cells, as discussed in this dissertation. Several factors relating to 
protein folding, protein stability, and epitope presentation are likely to blame for these failures. 
Misfolding of the soluble extracellular domain during production will yield molecules with 
the proper sequence but different conformations relative to the full length, cellularly expressed 
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target. Use of these misfolded proteins yield experimental failure due to loss of proper biological 
activity43,44. These domains may misfold because they are not stable enough to keep their structures 
in the absence of their transmembrane and intracellular domains or the cell membrane itself. 
Additionally, the production host may cause misfolding of these domains. The use of prokaryotic 
organisms, such as E. coli, as a production host can yield misfolded proteins due to the reducing 
environment of the cytosol, an under-abundance of molecular chaperones, and the inability to 
handle complex post-translational modification45. Eukaryotic microbes, such as yeast or other 
fungi, can produce misfolded or unfolded proteins due to environmental factors such as 
temperature, low pH, high osmolarity, and oxidative stress46. However, misfolded domains are 
challenging to characterize. The most definitive way to observe the fold of these proteins is through 
x-ray crystallography. Due to the challenges associated with crystallizing membrane proteins in 
their native conformations, relatively few of these structures exist 
(http://blanco.biomol.uci.edu/mpstruc/), meaning structural knowledge needed to characterize the 
accuracy of the fold of a soluble extracellular domain may not be available. Coupling this with the 
difficulty of adding x-ray crystallography as a standard quality control method for the multitude 
of soluble extracellular domains sold commercially, rigorous structural determination is unlikely 
feasible for implementation. The industry standard for quality control based on foldedness involves 
ELISA with a recombinant natural ligand or conformation-specific antibody, but assays like this 
fall short of the required rigor as they only characterize certain portions of the protein of interest, 
leaving the majority of the protein unexamined. 
Soluble extracellular domains often contain non-natural epitopes that would not be present 
on the full length transmembrane protein. These non-natural epitopes primarily originate from tags 
required for purification, immobilization, or selection as well as from the non-natural terminus 
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resulting from the absence of the transmembrane region. Tag molecules come in a variety of sizes, 
from small molecules like biotin (0.2 kDa) to protein fragments (e.g. human antibody Fc (26 kDa)) 
or full proteins (e.g., glutathione S-transferase (27 kDa)). When a tagged protein is used as the 
target for a ligand evolution campaign, the isolation of tag-binding ligands is a strong possibility. 
Even with appropriate depletion conditions to theoretically remove tag binders, binding to tags or 
tag complexes can still be observed38. Additionally, when tag molecules are added through non-
specific conjugation chemistries such as N-hydroxysuccinimide or maleimide, tag molecules can 
mask epitopes near the site of conjugation, removing these epitopes as targets for ligand binding. 
In addition to these non-natural epitopes, a soluble extracellular domain can also contain epitopes 
that would not normally be accessible in the full length protein due to steric hindrance by the 
presence of the transmembrane domain or the cell membrane itself. Binding to these epitopes 
would likely yield ligands that have no apparent activity against cellularly expressed target, despite 
the potential that the bound epitope was properly folded in the soluble extracellular domain. 
1.4. Ligand Selections Against Intact Mammalian Cells 
Performing ligand selections against intact mammalian cells avoids the target based issues 
highlighted for soluble extracellular domains in the previous section (Figure 1-2D). Selections 
using both phage display and yeast surface display against intact mammalian cells have been 
employed successfully to generate ligands that bind either specifically to a particular cell type or 
to a target of interest. 
Phage display selections against mammalian cells have shown success in generating cancer 
binding scFvs47 and peptides48, as well as scFvs against blood-brain barrier targets49. The most 
common selection method involves direct panning of phage display libraries against adhered cell 
monolayers50 or disadhered mammalian cells51. These selections are completed either with 
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subtractive depletion against target negative cells followed by enrichment against target-
expressing cells or with enrichment against target-expressing cells alone. Further innovation to 
this selection strategy involves additional approaches to deplete ligand that bind entities other than 
the target of interest. One such strategy, termed masked selection, involves first using a phage 
display library to generate binders to a target negative cell line, then producing those ligands as a 
polyclonal mixture to be used as a blocking agent for selections from the same library against a 
target positive cell line. Sequential depletions against disadhered cells have also been further 
optimized52. 
In an effort to further improve the efficiency of phage display cellular selections, laser 
capture microdissection has been developed53. In this method, target cells are affixed to a 
microscope slide and exposed to a phage display library. After binding occurs, cells from particular 
regions of tissue are recovered precisely by the laser capture microdissection instrument. This 
method has the advantage of being able to pan phage against a very small number of target cells 
(as low as 500 in a tissue). However, the drying conditions required to prepare the slides can 
contribute to decreased phage viability. 
Methods for phage display selections in vivo have been developed54,55 to generate ligands 
against tissues in their native environment. In this method, a phage display library is injected into 
a mouse and allowed to circulate for a very short amount of time. After the incubation period, the 
mouse is sacrificed and the tissue of interest is excised. Bound phage are propagated for further 
rounds of selection until dominant clone enrichment is observed. This method has the advantage 
of binding tissues in their native conditions, which likely have different protein expression levels 
relative to cells grown in vitro. However, care must be taken when using this method as phage 
viability suffers drastically with incubation times longer than a few minutes. 
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Yeast surface display panning selections against mammalian cells have also been 
successfully applied to the generation of target specific scFvs. Originally, FITC-binding scFvs 
were utilized to optimize conditions for panning against weakly adherent FITC-conjugated RBE4 
cells adhered to 6-well plates56. This method was directly applied to the isolation of scFvs that 
bind to blood-brain barrier receptors by the same group57. Other similar efforts yielded scFvs 
specific to B7-H458 and androgen-dependent prostate cancer59. 
Methods for selection against disadhered mammalian cells using yeast surface display have 
also been developed. One such method utilizes density differentiation centrifugation through 
Ficoll-Paque to isolate yeast-mammalian cell complexes60. Another study uses FACS with 
mammalian cells labeled intracellularly by carboxyfluorescein succinimidyl ester and yeast 
labeled by SYTO 61 nucleic acid stain to isolate yeast-mammalian cell complexes59. 
1.5. Overview of Work Completed in This Thesis 
The work discussed in this thesis aims to both further improve upon and apply cell-based 
selections using yeast surface display. These selections are shown to be robust across binding to 
multiple different target epitopes and to different targets. However, selection efficiency is shown 
to be strongly correlated to target expression on the mammalian cells. Rigorous optimization of 
the enrichment step for these selections reveals an increase in selectivity as the washing is made 
more stringent but a general inability to enhance recovery through modification of selection 
procedural details. Yet, redesign of the yeast surface display construct to add 40 additional amino 
acids of a polypeptide rich in alanine, serine, and proline61 greatly improves the ability to recover 
ligands characterized by micromolar affinity against mammalian cells that express on the order of 
one million targets per cell and the ability to recovery nanomolar affinity binders against 
mammalian cells that express on the order of one hundred thousand targets per cell. Using this 
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knowledge, libraries of two ligand scaffolds – fibronectin domain32 and affibody (Daniel 
Woldring, Patrick Holec, LAS, Yang Du, and Benjamin J. Hackel, in revision) – were sorted for 
binding against Thy1 and CD276 using soluble target and cell-based selection approaches to 
determine the most efficient method for generating translatable ligands. Cell-based selections 
employed either exclusively or in conjunction with soluble target methods were able to generate 
binders more effectively than selections via soluble target alone. However, isolated ligands had 
only modest affinity and a high frequency of non-specific binding ligands were isolated. These 
challenges motivated the development of affinity-based methods for cellular selection and methods 
for depleting non-specific binders from naïve libraries. Affinity-based selection was achieved by 
decreasing the number of ligands per yeast cell using dithiotreitol (DTT) to a range where affinity 
and avidity both drive the yeast-mammalian cell binding interaction rather than avidity alone. This 
method showed 16 ± 3-fold selectivity for a 2 nM EGFR-binding fibronectin domain relative to a 
17 nM EGFR-binding fibronectin domain. Application of this method to an EpCAM-binding 
fibronectin population yielded ligands with a median affinity of 24 nM relative to a median 1.6 
μM affinity for a population at the same stage of directed evolution sorted without affinity-based 
selection pressure. Separately, depletion of non-target binding ligands was achieved in a CD276-
binding model system by applying a pre-blocking step with disadhered target-negative mammalian 
cells, whereas an adherent cell depletion step yielded negligible selectivity. The disadhered 
blocking method yielded 10-fold selectivity for enrichment of a specific binder relative to a non-
specific binder. In total, this work improves the understanding and practical efficiency of cell-
based selection using yeast surface display, empowering a movement away from the use of soluble 
target domains and toward cell-based selection. This will likely improve the frequency of 
successful ligand engineering and allow the community to generate binding ligands against targets 
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that are difficult to produce properly in soluble form, such as G-protein coupled receptors, ion 
channels, and other multi-pass membrane proteins, and also to selection of ligands against cell 
types that don’t necessarily have a known biomarker, such as patient biopsies. 
  
14 
 
Chapter 2 – Geometry and Expression Enhance Enrichment of 
Functional Yeast-Displayed Ligands via Cell Panning 
Adapted with permission from “Stern, L.A.; Schrack, I.A.; Johnson, S.M.; Deshpande, A; Bennett, 
N.R.; Harasymiw, L.A.; Gardner, M.K.; Hackel, B.J.  “Geometry and Expression Enhance 
Enrichment of Functional Yeast-Displayed Ligands Via Cell Panning.”  Biotechnology and 
Bioengineering, 2016, 113 (11), 2328-2341.”  Copyright 2016 Wiley Periodicals, Inc. 
2.1. Abstract 
Yeast surface display has proven to be an effective tool in the discovery and evolution of 
ligands with new or improved binding activity. Selections for binding activity are generally carried 
out using immobilized or fluorescently labeled soluble domains of target molecules such as 
recombinant ectodomain fragments. While this method typically provides ligands with high 
affinity and specificity for the soluble molecular target, translation to binding true membrane-
bound cellular target is commonly problematic. Direct selections against mammalian cell surfaces 
can be carried out either exclusively or in combination with soluble target-based selections to 
further direct towards ligands for genuine cellular target. Using a series of fibronectin domain, 
affibody, and Gp2 ligands and human cell lines expressing a range of their targets, epidermal 
growth factor receptor and carcinoembryonic antigen, this study quantitatively identifies the 
elements that dictate ligand enrichment and yield. Most notably, extended flexible linkers between 
ligand and yeast enhances enrichment ratios from 1.4±0.8 to 62±57 for a low-affinity (>600 nM) 
binder on cells with high target expression and from 14±13 to 74±25 for a high-affinity binder (2 
nM) on cells with medium valency. Inversion of the yeast display fusion from C-terminal display 
to N-terminal display still enables enrichment albeit with 40% to 97% reduced efficacy. 
Collectively, this study further enlightens the conditions – while highlighting new approaches – 
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that yield successful enrichment of yeast-displayed binding ligands via panning on mammalian 
cells. 
2.2. Introduction 
Protein-based therapeutics have shown effectiveness in alleviating disease states as 
inhibitors, targeting agents for drug delivery, radioisotope carriers, and immune system engagers5. 
Engineered ligands have also been used for diagnostic purposes, such as targeted molecular 
imaging for patient stratification and treatment monitoring1 and ex vivo molecular analysis of blood 
and urine2–4. The landscape of clinical targets continues to grow with new genomic and proteomic 
discovery methods6. Moreover, biophysical constraints placed on the ligand for ‘developability’ 
require further ligand engineering62. To meet the demand for engineered ligands, numerous robust, 
high-throughput methods for selection of ligands with unique or improved specific binding activity 
have been developed. 
Yet, selections for ligands targeting cell surface receptors are often directed by the use of 
recombinantly produced soluble extracellular domains for previously characterized biomarkers. 
These target molecules are often immobilized on a solid support30,63 or labeled by a fluorescent or 
affinity tag for efficient screening26. While this selection strategy has yielded success in various 
campaigns, it has two major shortcomings. First, for known antigens, ligands with a binding 
phenotype to the soluble extracellular domain of the target of interest may not necessarily translate 
to binding effectively to target expressed on an intact cell. Potential causes include: 1) improper 
folding of the soluble target due to instability introduced by lack of transmembrane domain, 
storage conditions, or purification steps, 2) differential post-translational modification between the 
production host and the cell type of interest, 3) binding to a non-natural epitope resulting from the 
biological or chemical addition of tags to the target molecule to aid in purification or selection, or 
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4) lack of accessibility of the bound epitope in the presence of the transmembrane domain, cell 
membrane, and extracellular molecules. Second, these soluble target-based strategies are limited 
to targets that have been identified previously. Direct selection of ligands binding to mammalian 
cell surfaces overcomes these shortcomings. Target molecules are presented in their normal 
conformation with appropriate post-translational modification and no additional tags. Further, due 
to the wide array of cell surface proteins, cell-based selections can simultaneously be used as a 
proteomic strategy, allowing for discovery of previously uncharacterized protein expression while 
also evolving a ligand for the new target. 
The use of a genotype-phenotype linkage strategy allows for the screening of large 
combinatorial libraries of affinity proteins. One such genotype-phenotype linkage strategy is yeast 
surface display26,28. In yeast surface display, proteins of interest encoded by expression plasmids 
are produced as fusions with the yeast mating protein agglutinin 2 (Aga2p) and secreted. The 
fusion is tethered to the yeast cell surface in quantities of approximately 104-105 per cell by 
disulfide linkage with yeast protein agglutinin 1, which is anchored to the cell wall64. Yeast surface 
display has been successfully applied65 in screening for numerous ligands including, but not 
limited to, peptides36, antibody fragments66, and fibronectin domains67. Yeast surface display has 
been previously applied to cell-based selections. A protocol for these selections against cell 
monolayers has been optimized using fluorescein-labeled rat brain endothelial (RBE4) cells and 
anti-fluorescein single-chain antibody variable fragments (scFvs)56. Non-immune scFv libraries 
were effectively applied in ligand-biomarker co-discovery experiments using this optimized 
protocol to isolate ligands for receptors expressed by RBE4 cells57 and androgen-dependent 
prostate cancer cells 59. Other applications of this protocol include combination with soluble target-
based screening to ensure that isolated anti-B7-H4 scFvs would translate to binding true cellular 
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B7-H458 and isolation of mutants of the I domain of integrin Mac-1 that achieve high affinity 
conformations68. An alternative method for direct cellular selections utilizing disadhered 
mammalian cells and Ficoll density centrifugation for isolation of yeast-mammalian cell 
complexes has also been optimized 60.  
Although not evaluated in the current study, it should be noted that alternative display 
approaches have also been used for cellular selections. Phage display approaches have been 
employed successfully to generate cancer-specific scFvs47 and peptides48 by cellular selection. The 
small size of phage particles does afford the advantage of multiple different selection methods47 
including direct cellular selection against either adhered or disadhered cells69, microdissection 
methods53, and in vivo selections54. Although successful, phage display approaches can suffer from 
weak enrichment (often less than 10-fold per selection round)70,71. Phage display systems also do 
not have access to the eukaryotic translation machinery that yeast surface display employs, leading 
to lower functional diversity in phage display libraries relative to their yeast surface displayed 
counterparts31. Aptamers for several targets have also been developed72 by selections against 
whole cells73, selections against membrane preparations74, and in vivo selections75. 
This study aims to optimize and better understand the parameters for successful direct 
cellular selection using yeast surface display and cell monolayers. Incubation conditions, 
stringency of washing, target expression on mammalian cells, ligand expression on yeast cells, 
ligand binding affinity, ligand linker length and display orientation, location of bound epitope, and 
ligand protein scaffold were systematically varied to understand how each parameter affects 
enrichment ratio and yield of binding yeast in an EGFR-expressing model system. A strong 
expression dependence from the standpoint of the mammalian cell is shown. Further, the 
orientation of these interactions is significantly important. The addition of longer peptide linkers 
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extending the distance between the yeast cell surface and binding ligand aids recovery of binding 
ligands. Understanding and applying these parameters will aid in the application of this protocol 
for ligand selection experiments using a wide array of affinity protein scaffolds. 
2.3. Materials and Methods 
2.3.1 Cells and Cell Culture 
MDA-MB-468 and MDA-MB-231 were kind gifts from Professor Jayanth Panyam 
(Department of Pharmaceutics, University of Minnesota – Twin Cities). MCF7 and SKOV-3 were 
kind gifts from Professor Deepali Sachdev (Department of Medicine, University of Minnesota – 
Twin Cities). LS174T and MDA-MB-435 were kind gifts from Professor Tim Starr (Department 
of Obstetrics, Gynecology & Women’s Health, University of Minnesota – Twin Cities). A431 was 
a kind gift from Professor Daniel Vallera (Department of Therapeutic Radiology, University of 
Minnesota – Twin Cities). All cell lines were grown in DMEM with 4.5 g/L glucose, sodium 
pyruvate, and glutamine supplemented with 10% (v/v) fetal bovine serum. All cell lines were 
grown at 37 °C in a humidified atmosphere with 5% CO2.  
Yeast surface display was performed essentially as described27. Expression plasmids were 
transformed into EBY100 Saccharomyces cerevisiae yeast by EZ-Yeast Transformation (Zymo 
Research, Irvine, CA). Yeast harboring expression plasmids were grown in SD-CAA medium 
(16.8 g sodium citrate dihydrate, 3.9 g citric acid, 20.0 g dextrose, 6.7 g yeast nitrogen base, 5.0 
casamino acids in 1 L deionized H2O) at 30 °C with shaking. Protein expression was induced by 
transferring yeast cells in logarithmic phase (OD600nm<6) into SG-CAA medium (10.2 g sodium 
phosphate dibasic heptahydrate, 8.6 g sodium phosphate monobasic monohydrate, 19.0 g 
galactose, 1.0 g dextrose, 6.7 g yeast nitrogen base, 5.0 g casamino acids in 1 L deionized H2O) 
and growing at 30 °C with shaking for at least 8 hours, unless otherwise stated. EBY100 not 
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harboring plasmid were grown in YPD medium (10.0 g yeast extract, 20.0 g peptone, 20.0 g 
dextrose in 1 L deionized H2O) at 30 °C with shaking. 
 
2.3.2 Expression Plasmids 
The pCT plasmid26 was used as the expression vector for yeast surface display on the C-
terminus of Aga2p. The vector encodes for Aga2p followed by a 40-amino acid linker – including 
a Factor Xa cleavage site, an HA epitope, and a glycine-rich peptide – followed by the ligand with 
a C-terminal MYC epitope peptide (Table I). Fibronectin clones E6.2.6’39, E6.2.6’ N78S, E6.2.6’ 
AASV, EI4.4.239, EI3.4.339, WT’76, and C7.4.377, Gp2 clones GαEGFR2.2.338 and GαRIgG3.2.338, 
and affibody clones EA6878 and A5 (Daniel Woldring and Benjamin J. Hackel, unpublished) were 
cloned into pCT vector by NheI and BamHI restriction sites. 
Codons encoding for 20 or 40 additional amino acid residues, based on the PAS#1 
peptide61, within the linker between Aga2p and ligand were constructed by DNA assembly and 
ligated into pCT vector by PstI and NheI restriction sites, generating pCT-20 and pCT-40 vectors 
(Table 2-1). The construct for yeast surface display on the N-terminus of Aga2p was purchased as 
a full cassette (Integrated DNA Technologies, Coralville, IA) and ligated into pCT vector by EcoRI 
and XhoI restriction sites, generating pCTN vector. 
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Table 2-1. Relevant ligand and linker sequences 
 
2.3.3 Expression Level of Target Receptors 
EGFR and CEA expression on cell lines was quantified by flow cytometry in comparison 
to a calibration curve from anti-mouse IgG beads (Bangs Laboratories, Inc., Fishers, IN). 
Polystyrene beads with known quantities of immobilized monoclonal anti-mouse IgG were labeled 
with mouse anti-EGFR clone ab30 (10 μg/mL) or mouse anti-CEA clone ab4451 (20 μg/mL, 
Abcam, Cambridge, MA) for 30 minutes at room temperature.  Beads were washed once with 
phosphate-buffered saline with 0.1% bovine serum albumin (PBSA) and pelleted at 2,500g for 2.5 
minutes. The beads were then labeled by goat anti-mouse Alexa Fluor 647 conjugate (Life 
Technologies, Carlsbad, CA) for 30 minutes at 4°C, washed once with PBSA, and again pelleted 
at 2,500g for 2.5 minutes. Fluorescence was analyzed by flow cytometry using an Accuri C6 (BD 
Biosciences, San Jose, CA). 
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Mammalian cells were allowed to grow to 70-90% confluence. Culture medium was 
removed and the cells were washed once with 5 mL PBS. Cells were disadhered by trypsin-EDTA 
treatment for 3-7 minutes, and then quenched by the addition of serum-containing culture medium 
and centrifuged at 500g for 3 minutes. Culture medium was removed and cells were resuspended 
in PBSA and counted on a hemacytometer. Aliquots of 40,000 cells were pelleted at 500g for 3 
minutes at 4°C, then labeled with 20 μL ab30 (10 μg/mL) or ab4451 (20 μg/mL) for 30 minutes at 
4°C. Cells were washed once with PBSA and pelleted at 500g for 3 minutes. The cells were then 
labeled by goat anti-mouse Alexa Fluor 647 conjugate for 30 minutes at 4°C, washed once with 
PBSA, and again pelleted at 500g for 3 minutes at 4°C. Fluorescence was analyzed by flow 
cytometry using an Accuri C6. 
 
2.3.4 Yeast Surface Display Cell Panning 
Yeast surface display cell panning experiments were carried out following established 
protocols79. Cell lines were grown in 6-well plates to approximately 80% confluence, washed three 
times with ice cold PBSA, and kept at 4°C for the duration of the experiments. Yeast mixtures – 
with 1x108 plasmidless EBY100 yeast and 1x105 ligand-displaying yeast – were washed in PBSA 
and added to each well in 1 mL ice cold PBSA. Cells were incubated without shaking for 2 hours 
at 4°C. Cells were washed three times as described79 – tilted gently 25 times, and rotated 5 times 
until the final wash, during which plates were rotated 10 times – and detached by scraping into 1 
mL PBSA. Dilutions of recovered material were plated on SD-CAA plates to measure recovery of 
clone-expressing yeast. Dilution plating on YPD plates measured recovery of all yeast. This set of 
conditions constitutes the baseline for optimization experiments. 
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2.3.5 Optimization of Incubation and Washing  
To determine the optimal washing condition, the baseline conditions described above were 
repeated while varying the number of wash steps from one to five. For the one wash case, 1 mL 
ice cold PBSA was added to each well and plates were tilted gently 25 times and rotated 5 times. 
For the two wash case, a washing step involving only rotating the plate gently 10 times was added. 
For each subsequent case, steps of gently tilting 25 times and rotating five times were sequentially 
added. Recovery was quantified by dilution plating. 
In separate experiments, yeast populations were added to mammalian cells in 0.5 mL, 1 
mL, or 2 mL ice cold PBSA. Incubations were carried out according to the baseline conditions. 
After incubation, cells were washed three times and recovery was quantified by dilution plating. 
Following the addition of yeast populations to mammalian cells, plates were either nutated, 
allowed to be static, or immediately centrifuged (300 g for 3 min) and allowed to be static for the 
duration of incubation. After incubation, cells were washed three times and recovery was 
quantified by dilution plating. 
 
2.3.6 Influence of Ligand Expression on Selections 
Expression levels of fibronectin clones pCT E6.2.6’ and pCT E6.2.6’ N78S were 
modulated by modifying the duration of induction. Yeast clones were grown to OD=0.25 in SD-
CAA medium at 30°C with shaking. Yeast cells were then pelleted and changed to SG-CAA 
medium for induction. Aliquots of culture were removed 1, 2, 4, 8, and 24 hours post-induction. 
To quantify ligand expression, yeast were labeled with mouse anti-c-Myc primary antibody (9E10, 
BioLegend, San Diego, CA) followed by goat anti-mouse Alexa Fluor 647 conjugate and analyzed 
by flow cytometry. These samples were compared to a standard curve of anti-mouse conjugated 
beads similar to the EGFR expression experiments detailed previously. Upon choosing multiple 
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distinct expression levels, the effects of ligand expression on recovery in selections was tested 
under the baseline conditions previously described. 
 
2.3.7 Isolation of Dilute Binders by Multiple Round Selection 
To determine the number of rounds of cell panning until a binder dominates a population, 
mixtures of 108 WT’-displaying yeast and 7x104 or 105 binder-displaying yeast were screened 
against MDA-MB-468 or MDA-MB-231 using the four or five wash conditions. Yeast were 
recovered after each round, amplified in SD-CAA medium, and protein expression was induced in 
SG-CAA medium. For quantification, plasmid was recovered from 1x108 amplified yeast by 
zymoprep and analyzed using qPCR with clone-specific primers:  qRDGf: 
GTGAGCGACGTTCCAAGAGATC, qRDGr: GATAATTAATGCTGATCGGACGGCTG, 
q626’BCf:  TACTGATCAGCTGGTTCGACTACG, q626’r: 
GAAATTGGAGTAGAGCGAAAAGGC. 
 
2.3.8 Visualization of Binding Interactions by Phase Microscopy 
MDA-MB-468 and A431 were grown in 6-well plates to 70-90% confluence, washed with 
ice cold PBSA, and kept at 4°C for the duration of the experiment. 2.5x107 yeast displaying 
fibronectin clone pCT E6.2.6’ were introduced to monolayers in 1 mL ice cold PBSA and allowed 
to bind for 1.5 hours. Cells were washed 5 times with ice cold PBSA and visualized in phase mode 
using an EVOS FL Cell Imaging System (Thermo Fisher Scientific, Waltham, MA) with a 10X 
objective. 
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2.3.9 Visualization of Binding Interactions by Variable Angle TIRF Microscopy 
1x108 yeast displaying fibronectin clone E6.2.6’ were washed three times with PBS, then 
incubated with fluorescein isothiocyanate (FITC, 1 μg/mL) diluted in PBS for 45 minutes at room 
temperature in the dark. Excess FITC was quenched and removed by 3 washes with PBSA. 
MDA-MB-468 and A431 were grown to 80% confluence in 35 mm uncoated glass bottom 
dishes (MatTek Corporation, Ashland, MN). Cells were washed three times with PBS, then 
incubated with wheat germ agglutinin – Alexa Fluor 594 conjugate (1 μg/mL, Thermo Fischer 
Scientific, Waltham, MA) diluted in Hank’s balanced salt solution for 10 minutes at 37°C in the 
dark. Cells were then washed twice with ice cold PBSA to remove excess wheat germ agglutinin. 
FITC-labeled yeast were introduced to cells dropwise in 1 mL ice cold PBSA and allowed 
to bind for 1.5 hours. Cells were washed 5 times with ice cold PBSA. Cells were imaged using a 
Nikon Eclipse TiE microscope (Nikon, Melville, NY) using 488 nm and 561 nm lasers and 
variable angle TIRF (i.e., TIRF microscopy with the laser angle adjusted to view a deeper 
evanescent field). A Nikon CFI Apochromat 100X 1.49 NA oil objective and Andor iXon3 EM-
CCD camera fitted with a 2.5X projection lens was used to capture images with a 64 nm pixel size 
in a 512x512 pixel field of view. Full 3D volumes were recorded at 500-nm Z-steps for each 
randomly selected field of view (32-57 planes depending on the total thickness of all of the yeast 
and human cells present in the field of view).  Images were reconstructed using the FIJI software 
package. Maximal-intensity projections of the entire field of view volume were generated along 
the z-plane (axial view) and 3D projections were constructed with brightest point projection and 
rotation about the y-plane. 
The relative z-axis position of yeast bound to mammalian cells was quantified using the 
straight line selection tool for measurement in the FIJI software package. Two measurements were 
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taken:  the distance from the center of each individual bound yeast to the bottom of the interacting 
portion of the mammalian cell and the distance from the top to the bottom of the interacting portion 
of the bound mammalian cell. These distances were used to determine a normalized position for 
bound yeast relative to the z-dimensional thickness of the interacting portion of each mammalian 
cell (Figure 2-11E). 
 
2.4. Results 
2.4.1 Yeast Surface Display Cell Panning to Enrich Fibronectin Domains 
We sought to quantify the experimental elements that dictate success or failure in panning 
yeast-displayed ligands, particularly fibronectin domains, on mammalian cell monolayers. To 
determine if evolved fibronectin domains could be effectively enriched, the Shusta lab protocol79 
was used with highly expressing human cells (MDA-MB-468, 1.5±0.6x106 EGFR per cell) and a 
high-affinity ligand (fibronectin domain E6.2.6’, 2±2 nM affinity for EGFR). Indeed, the high-
affinity ligand was effectively enriched 112±66-fold relative to non-displaying yeast with 35±23% 
yield (Figure 2-1A,B). The baseline condition significantly outperforms the less stringent two-
wash and one-wash conditions by increasing enrichment (p=0.009 and p=0.02, respectively) and 
maintaining yield. Increasing the number of washes from three to five increases the enrichment 
ratio to 442±273 (p=0.003) while not significantly changing the binder yield (33±9%) in this 
context. Overall, enrichment follows a monotonic increasing correlation with number of washes 
(Spearman’s ρ=0.73, p<0.001). Notably, non-binding fibronectin mutant WT’ – wild-type human 
protein with the 77RGD79 tripeptide mutated to 77RDG79 to eliminate integrin binding – is not 
appreciably enriched under any of these conditions. 
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To study the impact of binding affinity on enrichment, a mutant ligand was engineered 
with reduced affinity. A yeast display library was created in which the entire fibronectin gene was 
mutated by error-prone PCR. Fluorescence-activated cell sorting was used to isolate mutants with 
reduced binding affinity to recombinant EGFR ectodomain. Several mutants were produced 
recombinantly in E. coli and titrated by flow cytometry for binding to A431 human epidermoid 
cancer cells. A single mutation in the FG loop, N78S, reduced binding strength to 17±4 nM. Using 
the mutant in yeast-mammalian cell panning experiments produced effective enrichment and a 
similar monotonic increase with an increasing number of washes (Spearman’s ρ=0.61, p<0.001) 
(Figure 2-1A,B). Notably, enrichment and yield were generally modestly reduced (median: 2.0-
fold; mean: 3.1-fold for enrichment) relative to the high-affinity ligand. To further evaluate the 
limit of weak affinity, additional affinity reduction was performed. Adding T16A, V45A, and I88V 
mutations to E6.2.6’ N78S results in weak binding at high concentrations (>600 nM affinity) in 
detergent solubilized cell lysate experiments with yeast surface display80. The low-affinity mutant, 
E6.2.6’ AASV, was not able to be definitively enriched relative to non-displaying yeast (1.3±0.9-
fold) using the five-wash condition. 
While the observed enrichment ratios and yields enable practical use, consistent with the 
aforementioned scFv studies, we attempted to elevate selection efficiency though modification of 
incubation conditions. Decreased incubation volume or centrifugation of selections prior to 
incubation were explored for potentially improved yeast-mammalian cell contacting. Increased 
incubation volume or nutation during incubation were tested for increased stringency against non-
specific yeast-mammalian cell interactions. For the high- and mid-affinity mutants, neither 
centrifugation nor reduction of incubation volume improved yields; moreover, enrichments 
relative to non-displaying yeast were decreased relative to baseline conditions (p=0.01 and p=0.01, 
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respectively; Figure 2-1,D). Increasing the incubation volume and adding nutation to incubation 
were also unable to increase enrichment ratio and yield for both clones tested (Figure 2-1C,D). 
Figure 2-1. The effect of washing and incubation conditions on enrichment ratio and recovery 
of yeast displaying fibronectin domain ligands panned on EGFRhigh cells. Yeast displaying 
E6.2.6’, E6.2.6’ N78S, and WT’ (affinities indicated) mixed 1:1,000 with non-displaying yeast 
were panned against EGFR-expressing MDA-MB-468. The enrichment and yield of binding 
ligands is presented as the mean ± standard deviation of 3-9 replicates.  (A and B) Selections 
were performed under baseline conditions with the exception of varied number of washing 
steps. (C and D) Selections were performed with the indicated modulation of incubation 
conditions.  
2.4.2 Multi-round Library Selections 
To further corroborate these data, we performed multi-round selections to evaluate the 
ability to isolate high-, mid-, or low-affinity ligands from a mock library of 105 binders and 108 
non-binders. Enrichment to 16% frequency was observed within two rounds for the high-affinity 
mutant. Within three rounds of panning, the high- and mid-affinity binders were dominant relative 
to non-binders whereas the low-affinity mutant was not noticeably enriched (Figure 2-2).
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Figure 2-2. Multi-round library selections.EBY100 yeast displaying fibronectin clones 
E6.2.6’, E6.2.6’ N87S, or E6.2.6’ AASV (affinities indicated) mixed 1:1,000 with yeast 
displaying WT’ were panned against MDA-MB-468 monolayers for multiple rounds 
in triplicate using the four wash condition. After each round, the fraction of yeast 
harboring plasmid encoding for the binding ligand was quantified by quantitative 
PCR.Effect of Target Expression on Cell Panning Efficiency  
To assess the impact of EGFR expression on panning performance, yeast displaying 
high- or mid-affinity fibronectin domains were panned on MDA-MB-231 breast cancer 
cells, which express 1.9±0.6x105 EGFR per cell (8-fold lower than MDA-MB-468). 
Enrichment was observed for high-affinity E6.2.6’ albeit with a lower ratio (14±13-fold 
enrichment over non-displaying (Figure 2-3A) as compared to 112±66 on highly 
expressing MDA-MB-468; p<0.001) and lower yield (2.2±1.9% (Figure 2-3B) as 
compared to 35±23%; p<0.001). Yield improved with reduced washing but at the expense 
of enrichment. Enrichment and yield for mid-affinity E6.2.6’ N78S were essentially non-
functional.  
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Figure 2-3. The effect of washing on enrichment ratio and recovery of yeast displaying 
fibronectin domain ligands panned on EGFRmid cells. Yeast displaying E6.2.6’, E6.2.6’ 
N78S and WT’ (affinities indicated) mixed 1:1,000 with non-displaying yeast were 
panned against MDA-MB-231. The enrichment (A) and yield (B) of binding ligands 
is presented as the mean ± standard deviation of 3-9 replicates. 
As MDA-MB-468 and MDA-MB-231 cells differ beyond simply EGFR expression 
levels, additional cell lines were evaluated (Figure 2-4A). In the context of the E6.2.6’ 
fibronectin / EGFR system, enrichment shows a strong positive monotonic correlation with 
target expression (Spearman’s ρ=0.72, p<0.001) (Figure 2-4B). Using the stringent five-
wash protocol, yeast displaying E6.2.6’ are enriched 410±273-fold versus non-displaying 
yeast when panned on MDA-MB-468 (1.5±0.6x106 EGFR/cell) and 15±10-fold on A431 
(2.9±1.4x106 EGFR/cell) but only 14±13 and 2.4±2.5 on mid-expressing cells (MDA-MB-
231 (1.9±0.6x105 EGFR/cell) and SKOV-3 (1.7±0.7x105 EGFR/cell), respectively), and 
only 2.8±3.3, 1.2±0.3, and 2.4±3.5 on low-expressing MDA-MB-435 (1.5±1.1x104 
EGFR/cell), LS174T (1.7±0.6x104 EGFR/cell), and MCF7 (1.2±1.5x102 EGFR/cell) cells 
(Figure 2-4). As a control, yeast displaying non-binding WT’ did not appreciably enrich 
on any cells. These results are consistent with the concept of multivalency in which 
numerous ligand-receptor interactions are needed to maintain durable cell-cell binding. Yet 
the superior performance on MDA-MB-468 versus A431 is unclear. 
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Figure 2-4. Enrichment across cell lines with varying EGFR expression and yeast cells 
with varying ligand expression. Yeast displaying E6.2.6’, E6.2.6’ N78S, and WT’ mixed 
1:1,000 with non-displaying yeast were panned using the five-wash condition against 
seven cell lines with varying EGFR expression. (A) Enrichment is presented as the 
mean ± standard deviation of 6-9 replicates. EGFR expression per cell, quantified by 
flow cytometry is indicated. M-468: MDA-MB-468. M-231: MDA-MB-231. M-435: 
MDA-MB-435. (B) Data from (A) for E6.2.6’ are plotted as enrichment vs. EGFR 
expression.  Yeast displaying E6.2.6’ and E6.2.6’ N78S with varying ligand expression 
mixed 1:1,000 with non-displaying yeast were panned against MDA-MB-468. The 
enrichment (C) and yield (D) of binding ligands is presented as the mean ± standard 
deviation of 3 replicates. Ligand expression, which varies because of different 
induction times, was quantified by flow cytometry. 
2.4.4 Effect of Yeast-Displayed Ligand Expression on Cell Panning Efficiency 
Given the impact of EGFR expression level on panning performance, we examined 
the effect of ligand expression at the previously described baseline conditions (Figure 2-
4C,D). A 2.9-fold reduction from 38,000 to 6,800 ligands/cell changes neither the 
enrichment ratio relative to non-displaying yeast nor yield of E6.2.6’ when panned against 
MDA-MB-468. A slight decrease in enrichment and yield of weaker affinity mutant 
E6.2.6’ N78S is observed with decreasing ligand expression, but these changes are not 
significant with the exception of one instance of a culture expressing 14,000 ligands/cell. 
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Regrowth of this clone with a similar ligand expression level (9,300 ligands/cell) shows 
similar enrichment (64±11 and 23±10) and yield (9±3% and 14±4%) to yeast expressing 
10,500 (50±20 and 10±1%) and 20,000 (24±10 and 17±2) ligands/cell, suggesting that the 
single trial showing weak enrichment and yield was an aberration. Enrichment ratio and 
yield of E6.2.6’ N78S at an expression level of 44,000 ligands/cell is statistically 
indistinguishable from E6.2.6’ at an expression level of 38,000 ligands/cell (p=0.2 and 
p=0.4, respectively). Overall, ligand expression does not drastically effect the enrichment 
and yield of binding clones in this context.  
 
2.4.5 Impact of Paratope 
While the strong performance on high-expressing cells – even for mid-affinity 
ligands – is encouraging, several applications would benefit from improved performance 
on mammalian cells expressing 104-105 targets. Notably, the fluorescein-binding antibody 
fragment system evaluated in the Shusta lab exhibited good yields (~20%) and enrichment 
(~60-fold) with 104 targets per cell56. Numerous experimental differences could explain 
the discrepancy including ligand type (antibody fragment versus fibronectin domain), 
target (fluorescein conjugated to cell surface molecules versus membrane-integrated 
EGFR), and geometric considerations: orientation of ligand paratope relative to yeast and 
orientation of target epitope relative to mammalian cell. 
To evaluate the impact of the receptor epitope and its orientation with regards to 
the mammalian cell or the presentation of the ligand paratope on yeast, three high-affinity 
fibronectin domains that bind various locations on EGFR81 were evaluated. E6.2.6’ binds 
EGFR in domain 1, EI4.4.2 binds EGFR domain 3, and EI3.4.3 binds EGFR at the domain 
3/4 interface (Figure 2-5A). When panned against high-expressing MDA-MB-468, EI4.4.2 
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showed significantly lower enrichment (92±83) than E6.2.6’ (410±273) (p = 0.002), 
suggesting some epitope dependence may exist. EI3.4.3 enriched strongly (233±157) at an 
intermediate level between E6.2.6’ (p=0.10) and EI4.4.2 (p=0.08) (Figure 2-5B,C). Yeast 
displaying each ligand were all similarly enriched on mid-expressing MDA-MB-231, 
though to a lesser extent relative to MDA-MB-468 (Figure 2-5D,E). 
 
Figure 2-5. The effect of epitope:paratope dependence on enrichment and yield. The 
epitopes for fibronectin domains E6.2.6’ (green), EI4.4.2 (red), and EI3.4.3 (blue) 81 
occur at different locations on the EGFR extracellular domain (1NQL) 82 (A). Yeast 
displaying the indicated clones mixed 1:1,000 with non-displaying yeast were panned 
against MDA-MB-468 (B,C) and MDA-MB-231 (D,E). The enrichment (B,D) and 
yield (C,E) of binding ligands is presented as the mean ± standard deviation of 6-12 
replicates. 
2.4.6 Effect of Linker Length and Ligand Orientation 
The fibronectin domains used in the previous experiments were displayed in the 
conventional yeast display format in which the C-terminus of Aga2p is fused to the N-
terminus of fibronectin via polypeptide linker. This format permits binding to recombinant 
EGFR ectodomain immobilized on magnetic beads – which was used for the discovery of 
these ligands39 – and cellular EGFR as evidenced by the effective panning results shown 
33 
 
up to this point. However, the N-terminus of fibronectin is proximal to the three engineered 
loops that comprise the presumed paratope (Figure 2-6). Additionally, the orientation of 
the N-terminus seemingly favors display of the fibronectin domain in an orientation in 
which the engineered loops are more frequently oriented towards the yeast cell surface. A 
longer linker aids separation of the fibronectin domain from the yeast surface and adds 
flexibility to reorient the ligand to prevent cell-cell steric hindrance. Fusion to the C-
terminus of fibronectin moves the linker distal to the engineered loops and seemingly 
favors display in which the engineered loops are more frequently oriented away from the 
yeast cell surface. 
 
 
Figure 2-6. Schematic of yeast surface display formats used in this study. The original 
pCT vector encodes a protein of interest expressed as a fusion to the C-terminus of 
Aga2p with a 40 amino acid linker (Aga2p-Fn). The designed pCTN vector encodes 
for a protein of interest as a fusion to the N-terminus of Aga2p with a 29 amino acid 
linker (Fn-Aga2p). The pCT-20 and pCT-40 constructs follow the same expression 
scheme as the original pCT, except 20- and 40-mer versions of the PAS#1 linker are 
added to the aforementioned 40 amino acid linker (Aga2p     Fn). 
Modified yeast display vectors were constructed to insert an additional 20 or 40 
amino acids – using the proline-alanine-serine (PAS#1) design61 – into the polypeptide 
linker between Aga2p and the fibronectin domain. 
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As high-affinity binders already achieve strong enrichment and yield when panned 
against highly-expressing cells, the extended linker has minimal further benefit (Figure 2-
9A,B). However, when panned against mid-expressing MDA-MB-231 cells, the extended 
linker improves enrichment for clone E6.2.6’ from 14±13 using the standard linker to 
74±24 with pCT-20 (p=0.001) and 35±9 with pCT-40 (p=0.002) and yield from 2.2±1.9% 
to 6.9±2.9% (p=0.008) and 7.8±1.7% (p<0.001) respectively (Figure 2-9C,D). A similar 
trend is seen using clone EI3.4.3, with the extended linker improving enrichment from 
11±19 to 148±55 (p=0.001) and 73±13 (p=0.002) and yield from 2±2% to 19±2% 
(p<0.001) and 30±21% (p=0.02) for standard linker, pCT-20, and pCT-40, respectively. 
Further, the low-affinity ligand – which lacks observable single-round enrichment with the 
standard linker even on highly expressing cells – can be effectively enriched on highly 
expressing cells when displayed with an extended linker: 62±57 for pCT-40 versus 1.3±0.9 
for standard linker (p=0.02). Unfortunately, the extended linker is not sufficient to enhance 
enrichment on mid-affinity ligands on mid-expressing cells. 
To further corroborate these data, multi-round selection experiments were 
conducted using the pCT and pCT-40 versions of E6.2.6’ and E6.2.6’ AASV in 1:1,500 
starting ratio with the equivalent pCT and pCT-40 versions of WT’. For selections against 
MDA-MB-468, pCT-40 E6.2.6’ AASV enriched to 64±15% of the pool after just two 
selection rounds, while pCT E6.2.6’ AASV required five rounds to reach 51±17% of the 
pool (Figure 2-9E). For selections against MDA-MB-231, pCT-40 E6.2.6’ enriched to 
96±24% of the pool after just two selection rounds, while pCT E6.2.6’ required four 
selection rounds to reach a comparable 98±4% (Figure 2-9F). Unfortunately, neither pCT 
E6.2.6’ AASV nor pCT-40 E6.2.6’ AASV were robustly enriched after five rounds. 
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Inverting the orientation from C-terminal fusion (Aga2p—Fn) to N-terminal fusion 
(Fn—Aga2p) maintains or hinders enrichment and yield on high- and mid-expressing cell 
lines for both high- and mid-affinity ligands (Figure 2-9). The enrichment ratio for high 
affinity clone E6.2.6’ decreases from 410±273 for the C-terminal fusion to 39±20 
(p=0.001) for the N-terminal fusion when panned against highly expressing MDA-MB-
468 cells. Enrichment for mid-affinity clone E6.2.6’ N78S decreases from 96±83 to 13±14 
(p = 0.057) when using the same cells. This trend holds for panning against mid-expressing 
MDA-MB-231 cells as well. For high-affinity EI3.4.3, enrichment is 233±157 for C-
terminal and 93±45 for N-terminal (p = 0.08). Notably, the expression level of multiple 
ligands tested on the yeast surface is comparable for N-terminal display and C-terminal 
display (Figure 2-7). 
 
Figure 2-7. Quantification of relative yeast surface display levels for pCT and pCTN 
expressed fibronectin domains. Yeast displaying fibronectin domains E6.2.6’, E6.2.6’ 
AASV, and EI3.4.3 as N-terminal and C-terminal fusions to Aga2p. Relative 
expression levels were quantified using flow cytometry. Data are shown as the ratio 
of pCTN/pCT fluorescence for each clone. 
Further exploration of the impact of paratope was conducted using the high-affinity 
CEA-binding fibronectin domain C7.4.3 to examine if the observed results are 
generalizable beyond fibronectin domain-EGFR complexes. When expressed as a C-
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terminal fusion to Aga2p with a 40-amino acid PAS linker and panned against LS174T 
human colorectal adenocarcinoma, the enrichment ratio (126±66) and yield (20±8%) 
remain quite strong, validating that fibronectin domains can bind other proteins on the 
mammalian cell surface in the yeast surface display context. Notably, LS174T cells 
expressed 4.4±4.5x104 CEA/cell on average although the distribution of CEA expression 
on a given day was much broader than EGFR expression on any cell line (Figure 2-8). In 
fact, the top 10% of highest expressers averaged 2.9±0.8x105 CEA/cell.  
 
Figure 2-8. Quantification of EGFR and CEA expression of Ls174T. EGFR and CEA 
expression for Ls174T was quantified using flow cytometry. CEA expression 
generally shows a wider distribution than EGFR expression. 
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Figure 2-9. The effect of varying linker length and display orientation on enrichment 
and yield. Yeast displaying EI3.4.3, E6.2.6’, E6.2.6’ N78S, and E6.2.6’ AASV mixed 
1:1,000 with non-displaying yeast were panned against MDA-MB-468 (A,B) or MDA-
MB-231 (C,D). C-terminal fusions (Aga2p-Fn) with the native linker, +20 linker, and 
+40 linker, as well as the N-terminal fusion (Fn-Aga2p) were tested. The enrichment 
(A,C) and yield (B,D) of binding ligands is presented as the mean ± standard deviation 
of 6-12 replicates. Yeast displaying E6.2.6’ or E6.2.6’ AASV as C-terminal fusions 
with the native linker or +40 linker were mixed 1:1,500 with WT’ displaying yeast in 
the native linker or +40 linker. Mixtures were panned in triplicate against MDA-MB-
468 (E) or MDA-MB-231 (F) monolayers for five rounds. After each round, the 
fraction of yeast harboring the binding ligand was quantified using quantitative PCR. 
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2.4.7 Effect of Ligand Protein Scaffold 
Spatial consideration can be further evaluated by testing alternative ligand 
scaffolds, which provide different paratope:epitope interactions as well as alternative 
display geometries. EGFR-binding fibronectin clone E6.2.6’, affibody clone EA68, and 
Gp2 clone GαEGFR2.2.3 were tested. In the C-terminal fusion construct, all three scaffolds 
effectively enriched against highly expressing MDA-MB-468 (Figure 2-10A,B). Non-
binding fibronectin clone WT’, affibody clone A5, and Gp2 clone GαRIgG3.2.3 showed no 
appreciable enrichment (data not shown). However, on mid-expressing MDA-MB-231, 
Gp2 clone GαEGFR2.2.3 exhibits significantly higher enrichment than either fibronectin 
clone E6.2.6’ (p=0.04) or affibody clone EA68 (p=0.035) (Figure 2-10C,D). The same 
holds true for yield (p<0.001 in both cases). Notably, the Gp2 scaffold has its N-terminus 
distal to the presumed paratope whereas the fibronectin and affibody do not. All three 
ligands show significant decreases in enrichment and yield when displayed as N-terminal 
fusions to Aga2p relative to their C-terminal fusion counterparts. Interestingly, the superior 
enrichment and yield of GEGFR2.2.3, relative to the fibronectin domain and affibody, are 
retained in the N-terminal fusion. The affibody variant exhibited lower enrichment than the 
other scaffolds on both cell types in both display orientations (p<0.05 for all scenarios 
(high- and mid-expression with N- and C-terminal display compared to fibronectin and 
Gp2) except p=0.07 for C-terminal display panned on mid-expressing MDA-MB-231 cells 
as compared to fibronectin). 
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Figure 2-10. The effect of protein scaffold on enrichment and yield. Yeast displaying 
fibronectin domain E6.2.6’, affibody domain EA68, and Gp2 domain GαE2.2.3 mixed 
1:1,000 with non-displaying yeast were panned against MDA-MB-468 (A,B) and 
MDA-MB-231 (C,D). Both N-terminal fusions and C-terminal fusions were tested. 
The enrichment (A,C) and yield (B,D) of binding ligands is presented as the mean ± 
standard deviation of 6-12 replicates. 
2.4.8 Microscopic Visualization of Mammalian Cell – Yeast Interaction  
MDA-MB-468 and A431 express similar levels of EGFR per cell, but panning 
against these cell lines using fibronectin clone E6.2.6’ shows much stronger performance 
when using MDA-MB-468. Microscopic visualization was employed to help better 
understand cellular interactions in this system. Phase microscopy was initially used to 
visualize a macroscopic view of the mammalian cell – yeast binding landscape (Figure 2-
11A,B). Visual inspection of the images corroborates panning data; many more yeast are 
seen binding to MDA-MB-468 than A431. In both cases, yeast are most often seen binding 
40 
 
at the interfaces between mammalian cells or the interface of a mammalian cell and the 
plate surface. Yeast are rarely seen binding to the middle of a mammalian cell unless the 
mammalian cell is particularly crowded with yeast. 
Variable angle TIRF microscopy was employed to gain a higher resolution, three-
dimensional view of these binding interactions (Figure 2-11C,D). Quantification of nine 
images using each cell line shows that the distribution of yeast binding locations are not 
appreciably different between both cell types (Figure 2-11E). The majority of yeast cells 
bound to the top portions of mammalian cells; very few yeast cells were found underneath 
mammalian cells. Variable angle TIRF images generally corroborated the phase 
microscopy images wherein the majority of yeast are found at mammalian cell – 
mammalian cell interfaces rather than in central portions of mammalian cells. 
 
Figure 2-11. Visualization of mammalian cell – yeast binding interactions.  (A,B) Yeast 
displaying fibronectin domain E6.2.6’ were introduced directly to monolayers of 
MDA-MB-468 (A) or A431 (B) for imaging by phase microscopy. (C-E) Yeast 
displaying fibronectin domain E6.2.6’ were labeled by fluorescein isothiocyante 
conjugation (green) and introduced directly to monolayers of Alexa Fluor 594 wheat 
germ agglutinin-labeled (red) MDA-MB-468 (C) or A431 (D) for imaging by variable 
angle TIRF microscopy. Mammalian cells are shown as a single z-slice through the 
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center. Yeast are shown by z-integration. Yeast binding interface position relative to 
the total height of the mammalian cell was quantified for both cell lines (E). 
2.5. Discussion 
Yeast surface display methods for direct cellular selections have shown success in 
the past, but applications have thus far been limited. We sought to gain a better 
understanding of how several parameters including washing stringency, incubation 
conditions, ligand and receptor stoichiometry, paratope location, yeast-displayed linker 
length and orientation, and ligand scaffold affect the ability to recover binding clones using 
these methods. The receptor expression levels, increased yeast-displayed linker length, and 
ligand scaffold had the most profound effects on the ability to enrich binding clones.  
Multiple small alternative protein scaffolds – fibronectin domain, affibody, and 
Gp2 – can be enriched by panning ligand-displaying yeast on target-expressing human cell 
monolayers as described for antibody fragment systems57. Enrichment is highly functional 
for mid-nanomolar affinity ligands when panned on human cells with millions of EGFR 
per cell (Figure 2-1 and Figure 2-2). Slightly improved enrichment is observed for a point 
mutant with low nanomolar affinity. Conversely, a mutant engineered via four point 
mutations for >600 nM affinity required five rounds of selection in the standard system for 
moderate enrichment. Though limiting to binder discovery, the reduced enrichment of 
lower affinity mutants can be advantageous for affinity discrimination to empower 
evolution of stronger binders. 
In addition to affinity, receptor density on the human cell surface strongly impacts 
ligand enrichment (Figure 2-3 and Figure 2-4). The strong, monotonic correlation between 
enrichment of binding clones and receptor expression is explained by an increase in avid 
interaction between yeast and mammalian cells. Without sufficient avidity, yeast are unable 
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to remain bound during washing and are lost. While limiting for enrichment of binders to 
some targets, selective enrichment based on receptor expression should aid the ability to 
isolate receptor-specific binders rather than binders to molecules ubiquitous, but lowly 
expressed on many cell types. 
However, the correlation between receptor density and enrichment is not perfect; 
enrichment using the A431 cell line was significantly lower than when using the MDA-
MB-468 cell line despite similar EGFR-expression levels. In order to better understand 
what causes this difference, TIRF microscopy was used to visualize yeast-mammalian cell 
binding interactions for both cell lines. In both cases, yeast tend to bind above the 
mammalian cells; there is no appreciable difference in the location of the binding interfaces 
despite a significant difference in morphology. Thus, the differences in enrichment do not 
appear to be differences in cellular-level physical characteristics. Although it is beyond the 
scope of this study, differences on a molecular level such as disparate receptor clustering 
could explain these differences. 
Differing from the receptor expression results, decreased avidity with respect to 
yeast-displayed ligand expression does not show a significant impact on the ability to 
enrich binding clones (Figure 2-4). Notably, even with substantial variance in culture 
induction times (1 – 24 hours), the display of fibronectin domains only varied 3.5-fold. 
This expression level appears to still allow for the minimum functional avidity for recovery 
in the context of this experiment. Thus, the lack of impact on enrichment was likely 
partially driven by the small valency range evaluated. It remains to be determined if a yeast 
system engineered for ultra-high valency would provide improved enrichment. Moreover, 
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we could not readily obtain very poor expression with our model system to evaluate lower 
valency conditions that may result from certain proteins or alternative display methods. 
Fibronectin enrichment was broadly effective as evolved variants targeting three 
different EGFR epitopes were robustly enriched on highly expressing MDA-MB-468 cells 
(Figure 2-5). Moreover, a CEA-binding fibronectin was enriched 130±70-fold on LS174T 
cells. Breadth was further evaluated by testing three alternative small protein scaffolds: 10 
kDa -sandwich fibronectin domain, 7 kDa -helical bundle affibody, and 5 kDa  Gp2 
domain (Figure 2-10). EGFR-binding variants of all three were strongly enriched (210±50 
to 680±410-fold) on highly expressing MDA-MB-468 cells and at least modestly enriched 
(5±2 to 130±110-fold) on mid-expressing MDA-MB-231 cells. Despite the fact that the 
Gp2 variant tested has modestly weaker affinity than the affibody and the fibronectin, 
GEGFR2.2.3 outperformed these molecules on both cell lines. Moreover, the affibody 
variant EA68 had the lowest enrichment of the three tested scaffolds. These differences 
may be caused by paratope orientation or epitope accessibility. The presumed paratope of 
Gp2 is distal to its termini, which may reduce steric hindrance from the linker and/or the 
yeast surface to allow better accessibility in binding. Conversely, the affibody and 
fibronectin scaffolds have N-termini proximal to the evolved regions. It is important to 
note that general conclusions cannot be drawn from these scaffold comparisons because 
the observations relate to only one variant for each. In order to make stronger 
generalizations, additional variants from each scaffold type should be tested. Moreover, 
while numerous scaffolds, ligand mutants, and cell lines were used throughout to aid 
generalizability, experimental specifics should be carefully considered when analyzing 
data to differentiate between general principles and case-specific results. 
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Though advantageous for affinity discrimination and target specificity, the limited 
enrichment when using low-affinity ligands or mid-expressing cell monolayers can limit 
some applications. We hypothesized that an extended linker between the Aga2p tethering 
domain and the ligand could aid the ability for ligand to engage with receptor. The addition 
of a 40-mer PAS linker, based on the PAS#1 peptide (Table 2-1)61, allowed for successful 
enrichment of E6.2.6’ AASV, the >600 nM affinity clone, using MDA-MB-468 (Figure 2-
9). The ability to enrich molecules of such modest affinities is important for many 
applications, such as mimicking immune cell interactions and isolating binders from naïve 
combinatorial libraries to initiate directed evolution of new activity. Further, longer linkers 
allow for 2.5- to 13-fold improved enrichment of strong affinity clones E6.2.6’ and EI3.4.3 
against the MDA-MB-231 cell line, which has 8-fold lower EGFR expression than MDA-
MB-468. This broadens the reach of yeast panning for target-ligand co-discovery by 
strengthening enrichment on cells with upregulated target expression, albeit only to a 
~200,000 target/cell level, which is the case for many important biomarkers. The enhanced 
enrichment also allows for differential affinity discrimination dependent on target density 
and affinity. Further experiments would be needed to identify the optimal linker length that 
balances gains in accessibility with potential detriments. 
While extended linkers aided enrichment, changing the yeast surface display 
construct from Aga2p—ligand to ligand—Aga2p (Figure 2-6) did not; rather performance 
was generally decreased when ligands were fused to the N-terminus of Aga2p. These 
results were counter to the hypothesis that this orientation would enhance accessibility for 
fibronectin and affibody paratopes. While the polypeptide linker lengths were not equal 
(29 amino acids in ligand—Aga2p and 40 amino acids in Aga2p—ligand), this was 
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designed to match distance between the yeast surface and the evolved fibronectin loops; 
i.e. to account for the length of the conserved fibronectin framework in the ligand—Aga2p 
construct (Figure 2-6). Notably, many of the clones tested were matured as C-terminal 
fusions to Aga2p. Changing the anchor point of these ligands may contribute to this 
decrease in performance and is not recommended for future ligand evolution campaigns. 
2.6. Conclusions 
In conclusion, yeast displaying small ligands of at least 20 nM affinity were readily 
enriched by panning on human cell monolayers expressing millions of targets per cell. 
Extension of the polypeptide linker by 20 or 40 amino acids enabled enrichment of a µM-
affinity binder and improved enrichment of nM-affinity binders on cells expressing 105 
targets per cell. Yeast display as C-terminal fusion to Aga2p yielded broadly superior 
enrichment relative to N-terminal fusion for the molecules tested; thus, orientation should 
be carefully considered in future use. These considerations can be applied to direct cellular 
selections both for ligand evolution against known biomarkers and ligand-biomarker co-
discovery experiments using a variety of ligand scaffolds. Ultimately, the findings of this 
study will increase the efficiency of ligand discovery by removing the challenge of 
translatability presented by current soluble target-based selection methods.  
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Chapter 3 – Cellular-Based Selections Aid Translational 
Binding in Yeast Display Ligand Discovery: Targeting Oncology 
Vascular Biomarkers CD276 and Thy1 
Adapted from: Stern L.A., Woldring D.R., Abou-Elkacem L., Willmann J.K., and Hackel 
B.J.  “Cellular-Based Selections Aid Translational Binding in Yeast Display Ligand 
Discovery:  Targeting Oncology Vascular Biomarkers CD276 and Thy1.”  In preparation 
for submission. 
3.1. Abstract 
Yeast surface display is a proven tool for the selection and evolution of ligands with 
novel binding activity. Selections from yeast surface display libraries against 
transmembrane targets are generally carried out using recombinant soluble extracellular 
domains. Unfortunately, these molecules may not be good models of their true, membrane-
bound form for a variety of reasons. In these instances, ligand selection campaigns often 
end in failure. Advances in cell-based selections with yeast surface display may aid the 
frequency of evolving ligands that do bind true, membrane-bound antigens. This study 
aims to rigorously compare five ligand selection strategies using both soluble target-driven 
and cellular selection techniques to determine which methods yield translatable ligands 
most efficiently and generate novel binders against CD276 and Thy1, two promising tumor 
vasculature targets. Out of four ligand selection campaigns carried out using only soluble 
extracellular domains, only an affibody library sorted against CD276 yielded translatable 
binders. In contrast, fibronectin domains against CD276 and affibodies against Thy1 and 
CD276 were discovered in campaigns that either combined soluble target and cellular 
selection methods or used cellular selection methods alone. Collectively, this study 
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motivates the addition of cellular selections to ligand evolution pipelines as well as 
introduces promising fibronectin domain and affibody molecules specific to Thy1 and 
CD276. 
3.2. Introduction 
Advances in genomic and proteomic methods6 have increased knowledge of 
disease biomarkers at a rate that has outpaced the development of new molecularly targeted 
agents for diagnosis and therapy. Several classes of molecules can be applied to bridge this 
gap including engineered proteins83–85. A variety of scaffolds have shown therapeutic 
effectiveness as inhibitors, targeting agents for drug delivery, radioisotope carriers, and 
immune system engagers5 and diagnostic success for early disease detection, patient 
stratification, and treatment monitoring1. 
Numerous high-throughput screening methods for selection of engineered proteins 
with novel specific binding activity have been applied. Most often, the discovery of ligands 
targeting cell surface receptors is directed by the use of recombinantly produced soluble 
extracellular domains. The use of these molecules as selection targets allows for efficient 
screening via immobilization on solid supports30,63 or fluorescent tagging26. However, 
these targets are unlikely to be perfect models of full length target expressed on intact cells 
due to several factors including: a) improper folding of the soluble domains43–46, b) 
differential post-translational modification due to the production host34,86, c) presence of 
non-natural epitopes resulting from the biological or chemical addition of tags for 
purification and/or selection38, and d) possible exposure of epitopes that would not be 
accessible to ligands in the presence of the transmembrane domain or cell membrane. 
Despite selection against these molecules yielding successful engineered ligands in 
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numerous cases11,39,40, many ligand engineering campaigns end in failure due to the 
inability of isolated soluble domain binding ligands to bind full length target expressed on 
intact cells (LAS and BJH, unpublished). As there is no good outlet, these results are 
seldom reported, skewing perception of the difficulties of ligand discovery. 
This study aims to rigorously compare five different ligand selection methods to 
determine how best to robustly generate ligands that bind intact, extracellularly expressed 
target molecules using tumor vasculature biomarkers thymocyte differentiation antigen 1 
(Thy1) and CD276 as targets for fibronectin domain12,87 and affibody88,89 yeast surface 
display libraries. Thy1 overexpression in the neovasculature of pancreatic ductal 
adenocarcinoma differentiates the diseased tissue from normal pancreas or chronic 
pancreatitis, allowing for detection of disease with superior sensitivity and specificity 
relative to the current standard of care90. CD276 overexpression in the vasculature of early 
stage ovarian cancer differentiates diseased tissue from corpus luteum and benign ovarian 
tumors91. These characteristics make both molecules attractive targets for molecular 
ultrasound imaging as well as other diagnostic and therapeutic applications. The selection 
methods examined in this study include: 1) magnetic bead sorting27,30 and fluorescence 
activated cell sorting (FACS)26,27 using biotinylated soluble extracellular domains, 2) 
magnetic bead sorting using biotinylated soluble extracellular domains followed by FACS 
with detergent soluble cell lysate79,80, 3) magnetic bead sorting using biotinylated soluble 
extracellular domains followed by direct yeast panning on adherent cell monolayers33,56,79, 
4) direct yeast panning on adherent cell monolayers, and 5) direct yeast panning on 
adherent cell monolayers preceded by magnetic bead depletion using biotinylated soluble 
proteins. Magnetic bead sorting enables very high valency (up to five million targets per 3 
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µm magnetic bead) and efficiently scalable volumes. Fluorescence-activated cell sorting 
enables stringent quantitative analysis for fine affinity and selectivity discrimination. 
Detergent solubilized cell lysate provides complete membrane-spanning protein albeit in a 
modified detergent context. Direct yeast panning on adherent cell monolayers provides 
complete target in the full cellular context though the nature of cell-cell (yeast-human) 
interactions is fundamentally different than cell-protein interactions in the other modes of 
selection. 
Clonal characterization shows that campaigns utilizing cellular-based enrichment 
in part or entirely (6/12 campaigns) have a higher success rate for yielding at least one 
target-specific cellular binder relative to campaigns relying on completely soluble 
extracellular domains for enrichment (1/4 campaigns). The ability of selections using 
soluble extracellular domains to yield target-specific cellular binders appears to be 
dependent on both the target molecule and ligand library used. Application of more 
robustly successful ligand selection methods will improve the efficiency and quality of 
molecular targeting agents for disease state biomarkers. 
 
3.3. Materials and Methods 
3.3.1 Cells and Cell Culture 
Mile Sven 1 cells stably transfected to express human CD276 (MS1-CD276)91 or 
human Thy1 (MS1-Thy1)90 were grown at 37 °C in a humidified atmosphere with 5% CO2 
in DMEM with 4.5 g/L glucose, sodium pyruvate, and glutamine supplemented with 10% 
(v/v) fetal bovine serum.  
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Yeast surface display was performed essentially as described27. EBY100 yeast 
harboring expression plasmids were grown in SD-CAA medium (16.8 g/L sodium citrate 
dihydrate, 3.9 g/L citric acid, 20.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L 
casamino acids) at 30 °C with shaking. Protein expression was induced by transferring 
yeast cells in logarithmic phase (OD600nm<6) into SG-CAA medium (10.2 g/L sodium 
phosphate dibasic heptahydrate, 8.6 g/L sodium phosphate monobasic monohydrate, 19.0 
g/L galactose, 1.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L casamino acids) and 
growing at 30 °C with shaking for at least 8 h. EBY100 without plasmid were grown in 
YPD medium (10.0 g/L yeast extract, 20.0 g/L peptone, 20.0 g/L dextrose) at 30 °C with 
shaking. 
 
3.3.2 Library Construction and Characterization 
Oligonucleotides encoding for the second generation sitewise gradient hydrophilic 
fibronectin domain library32 and second generation sitewise gradient affibody library 
(DRW, Patrick Holec, LAS, Yang Du, and BJH, unpublished) were synthesized by IDT 
DNA Technologies. Full length amplicons for each respective library were assembled by 
overlap extension PCR and homologously recombined into pCT-40 yeast surface display 
vector, with a linker extended by 40 additional amino acids33, within yeast strain EBY100 
by electroporation transformation as previously described32. Transformation efficiency 
was quantified by dilution plating on SD-CAA agar plates.  
Full-length library construction was characterized by simultaneous labeling of the 
N-terminal hemagglutinin (HA) epitope and C-terminal c-Myc epitope by flow cytometry. 
Two million yeast were pelleted at 12,000g for 1 min, washed once with PBS with 1 g/L 
bovine serum albumin (PBSA), then labeled with mouse anti-c-Myc antibody 9E10 (0.5 
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μg/mL, BioLegend, Cat: 626802) and biotinylated goat anti-HA polyclonal antibody (2 
μg/mL, Genscript, Cat: A00203) for 30 min at room temperature. Cells were washed once 
with 1 mL PBSA, labeled by goat anti-mouse Alexa Fluor 647 conjugate (10 μg/mL, Life 
Technologies, Cat: A-21235) and streptavidin Alexa Fluor 488 conjugate (2 μg/mL, Life 
Technologies, Cat: S11223) for 15 min at 4 °C, and washed once. Fluorescence was 
analyzed by flow cytometry (Accuri C6, BD Biosciences). 
 
3.3.3 Magnetic Bead Selections with Soluble Extracellular Domains 
Recombinant human Thy1 extracellular domain Fc fusion (Thy1-Fc) (Abcam, Cat: 
ab157072) was biotinylated on free amines using EZ-Link NHS-PEG4-Biotin (Thermo 
Fisher Scientific, Cat: 21330). Biotinylation was verified using matrix-assisted laser 
desorption ionization mass spectrometry (Sciex 5800, Applied Biosystems). Recombinant 
human CD276 extracellular domain (Sino Biological, Cat: 11188-H08H-B) was obtained 
already biotinylated. 
Magnetic bead selections were carried out as essentially previously described 30 
using 15-fold oversampling of ligand diversity at all stages. For the first round of selection, 
libraries were depleted of magnetic bead binders three times with streptavidin coated 
Dynabeads (Thermo Fisher Scientific, Cat: 11205D). Remaining yeast were incubated with 
CD276 or Thy1-Fc coated magnetic beads at 4 °C and washed twice with ice cold PBSA. 
Beads with attached cells were resuspended in SD-CAA for growth. Magnetic beads were 
removed using a Dynal magnet prior to the induction of protein expression for the next 
round of selection. For subsequent rounds, non-specific binders were depleted with 
streptavidin coated magnetic beads and negative control protein coated magnetic beads 
prior to enrichment with target coated magnetic beads. Selections were carried out at room 
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temperature and target-coated beads were washed three times with PBSA before regrowth 
of the attached yeast. Dilution plating on YPD plates of all negative control and target-
coated bead populations was completed to quantify enrichment. 
 
3.3.4 FACS with Soluble Extracellular Domains 
Fluorescence-activated cell sorting (FACS) was carried out essentially as described 
27. Induced yeast were simultaneously labeled with anti-c-Myc antibody and 10-100 nM 
biotinylated target protein or biotinylated negative control protein for at least 30 min at 
room temperature. Cells were washed once with PBSA, labeled with goat anti-mouse 
Alexa Fluor 647 conjugate and streptavidin Alexa Fluor 488 conjugate for 15 min at 4 °C, 
and washed with 1 mL PBSA. Cells with the highest binding : ligand display ratio 
(AlexaFluor488:AlexaFluor647) were sorted using a FACSAria (BD Bioscience). 
 
3.3.5 FACS Selections with Detergent Solubilized Cell Lysates 
Detergent solubilized cell lysates were prepared essentially as described 79. MS1-
Thy1 and MS1-CD276 cells were grown to 70-90% confluence in 75 cm2 tissue culture-
treated T-flasks. Culture medium was removed and the cells were washed once with 5 mL 
PBS. Cells were detached by trypsin-EDTA treatment for 4-7 minutes, quenched with 
serum-containing culture medium, and centrifuged at 500g for 3 min. Pelleted cells were 
washed three times with ice cold PBS and pelleted at 300g for 3 min at 4 °C. Washed cells 
were resuspended in PBS with 0.5 mg/mL fresh sulfo-NHS-biotin (Thermo Fisher 
Scientific), rotated for 30 min at room temperature, and washed twice with ice cold PBSA 
to quench and remove excess biotin. Cells were resuspended in 100-200 μL FACS lysis 
buffer (PBS with 1% (v/v) Triton X-100, 2 mM EDTA, and 1x cOmplete protease inhibitor 
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cocktail (Roche) and incubated with rotation at 4 °C for 15 min. Cell debris was pelleted 
at 15,000g for 30 min at 4 °C and removed. Induced yeast were washed once with PBSA, 
then incubated with cell lysate and mouse anti-c-Myc antibody (2.5 μg/mL) simultaneously 
for 2 h at 4 °C with rotation. Yeast were washed with 1 mL ice cold PBS containing 1% 
(v/v) Triton-X 100 and then with 1 mL ice cold PBSA. Cells were incubated with goat anti-
mouse Alexa Fluor 647 conjugate (10 μg/mL) and streptavidin Alexa Fluor 488 conjugate 
(2 μg/mL) at 4 °C for 15 min, and washed with 1 mL ice cold PBSA. Cells with the highest 
binding:ligand display ratio (AlexaFluor488:AlexaFluor647) were sorted using a 
FACSAria. 
 
3.3.6 Yeast-Cell Panning Selections 
Cell panning selections were carried out essentially as described 33. Mammalian 
cells were grown in 6-well plates to approximately 90% confluence. Culture medium was 
removed and cells were washed three times with ice cold PBSA with 1 mM CaCl2 and 0.5 
mM Mg2SO4 (PBSACM). For the first round of selection, 2.4x109 yeast (three-fold 
diversity of Fn library, six-fold diversity of Affibody library) were washed once with ice 
cold PBSACM, resuspended to 1x108 yeast/mL in ice cold PBSACM, and applied to 
mammalian cells in 1 mL aliquots dropwise. Cells were incubated without shaking for 2 h 
at 4 °C and unbound yeast were removed by aspiration. Cells were washed with 1 mL ice 
cold PBSACM four times with 25 gentle tilts and 5 nutations and one time with 10 
nutations. Bound yeast were recovered by scraping cell monolayers and resuspending them 
in SD-CAA growth medium. Yield was quantified by dilution plating on YPD plates. For 
each subsequent round, at least 15-fold of the recovered yield were washed and 
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resuspended to no more than 1x108 yeast/mL in ice cold PBSACM. Yeast were panned, in 
parallel, against one target-positive and two target-negative cell lines.  
 
3.3.7 Clonal Characterization of Sorted Populations by Yeast-Cell Panning 
Forty-eight colonies from each selection campaign, obtained by plating yeast 
populations on SD-CAA, were picked and resuspended in 1 mL SG-CAA in deep-well 96-
well plates. Plates were covered and grown at 30 °C with shaking for at least 8 h. 
Target-positive and target-negative mammalian cells were grown to approximately 
80% confluence in 24-well plates. Cells were washed 3 times with ice cold PBSACM. 250 
μL of induced clonal yeast was added dropwise directly to one well of target-positive and 
one well of target-negative mammalian cells. Cells were incubated without shaking for at 
least 2 h at 4 °C. Cells were washed with 250 μL ice cold PBSACM twice with 25 gentle 
tilts and 5 nutations and once with 10 nutations. Yeast binding was visualized using EVOS 
FL Cell Imaging System (Thermo Fisher Scientific) at 40x total magnification.  
Individual clone binding was categorized as -, +, ++, or +++ through counting 
associated yeast in a random microscope field. Clones were characterized as “-“ if fewer 
than 15 yeast were observed, “+” if 15 to 50 yeast were observed, “++” if greater than 50 
yeast were observed but mammalian cells were still visible, and “+++” if yeast were the 
dominant organism seen in the frame (Figure 3-5). 
 
3.3.8 DNA Sequencing 
Plasmid DNA from yeast clones that bound target-positive but not target-negative 
cells was recovered by zymoprep of 200 μL of each individual clone. Ligand sequences 
were amplified in 50 μL PCR mixtures containing 2 μL zymoprep DNA, 1x Phusion High 
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Fidelity buffer, 0.5 μM each of primers W5 and W3 67, 0.2 mM dNTP mixture, and 2.5 U 
Phusion polymerase (New England Biolabs, Ipswich, MA). PCR products were purified 
by agarose gel electrophoresis and Sanger sequenced with GeneAmp5 primer (5’-
CGACGATTGAAGGTAGATACCCATACG-3’) (Eurofins MWG Operon, Louisville, 
KY). 
 
3.3.9 Affinity Maturation of Fibronectin Domains 
Random mutation of fibronectin domains was performed essentially as described 67 
by error-prone PCR with nucleoside analogs 92. Zymoprepped plasmid DNA was mutated 
by error-prone PCR of full fibronectin domain genes using primers W5/W3 67 and 
fibronectin loops using primers BCHPEP5/BCHPEP3, DEHPEP5/DEHPEP3, and 
FGHPEP5/FGHPEP3 32. PCR products were purified by agarose gel electrophoresis, 
amplified in four 200 μL PCR mixtures, concentrated by ethanol precipitation, and 
resuspended in 30 μL buffer E several hours before electroporation. Mutated sublibraries 
were homologously recombined with linearized pCT-Gene (cut with NdeI, PstI-HF, and 
BamHI-HF) or pCT-40-FnHP-Loop (cut with SmaI, NcoI-HF, and NdeI) in EBY100 yeast 
by electroporation transformation as described 32. Transformation efficiency was 
quantified by dilution plating on SD-CAA plates. 
 
3.3.10 Clone Production 
Gel-purified PCR amplicons were digested by NheI-HF and BamHI-HF (New 
England Biolabs) and ligated into a pET-22b vector containing a C-terminal His6 tag 
(Novagen, EMD Millipore, Billerica, MA) using T4 DNA ligase (New England Biolabs). 
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Plasmids were transformed via heat-shock into T7 E. coli (New England Biolabs) and 
plated on lysogeny broth (LB) (10.0 g/L tryptone, 5.0 g/L yeast extract, 10.0 g/L sodium 
chloride) agar plates containing kanamycin (50 mg/L). Clones were verified by Sanger 
sequencing of plasmids recovered by bacterial miniprep (Epoch Life Science, Sugar Land, 
TX). 
E. coli were grown to saturation in 5 mL LB containing kanamycin at 37 °C with 
shaking. Cultures were diluted to OD600 = 0.03 with 100 mL LB in 250 mL baffled culture 
flasks. At OD600 = 0.5 - 1.0, protein expression was induced with 0.5 mM isopropyl β-D-
1-thiogalactopyranoside overnight at 30 °C with shaking. Cells were pelleted at 3220g for 
20 min, resuspended in bacterial lysis buffer (50 mM sodium phosphate (pH 8.0), 0.5 M 
sodium chloride, 5% glycerol, 5 mM CHAPS, and 25 mM imidazole) and subjected to 5 
freeze-thaw cycles. Insoluble cell debris was removed by centrifugation at 10,000g for 10 
min followed by filtration (0.2 µm). Protein was purified by metal affinity chromatography 
on 2 mL of Cobalt HisPur Resin according to the manufacturer’s protocol (Thermo Fisher 
Scientific). Purity was assessed by SDS-PAGE using 4-12% bis-tris gels (Life 
Technologies, Carlsbad, CA). Protein concentration was quantified by absorbance at 280 
nm 93. 
 
3.4. Results 
 
3.4.1 Ligand Selections using Soluble Extracellular Domain Driven Methods 
Twenty ligand selection campaigns were carried out using two ligand scaffold 
libraries – fibronectin domain and affibody – to generate binders to two vascular 
biomarkers – Thy1 and CD276 – via five selection approaches. Three approaches used 
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soluble extracellular domains as the primary target, with recombinant extracellular domain 
FACS selections, detergent solubilized lysate FACS, or yeast-cell panning selections added 
as translatable sorts after sufficient monovalent affinity for soluble domains was 
established (Figure 3-1). 
 
Figure 3-1. Schematic of the sorting methods examined. An affibody library and a 
fibronectin domain library was sorted for ligands that bound CD276 or Thy1 
specifically. Libraries were sorted by five different schemes: 1) magnetic bead 
selection with recombinant extracellular domains followed by FACS with 
recombinant extracellular domains, 2) magnetic bead selection followed by FACS 
with detergent solubilized cell lysate, 3) magnetic bead selection followed by cell 
panning selection, 4) cell panning selection with magnetic bead depletion, and 5) cell 
panning selection. 
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Ligand selections using magnetic bead sorting and FACS with only soluble 
extracellular domains successfully generated ligands that bind their target with at most 100 
nM target (Figure 3-2). Ligands from both campaigns isolated against CD276 appear to 
have high specificity for their targets, showing no cross-reactivity with streptavidin, the 
reagent used for both immobilization and fluorescent labeling in all sorts. Ligands evolved 
against Thy1-Fc, despite depletion during magnetic bead selection with human IgG, do still 
show a significant amount of cross reactivity for human IgG, suggesting that depletion was 
not complete enough. However, ligands specific to Thy1 were still sortable from the overall 
population through gating to exclude the cross-reactive clones. 
 
Figure 3-2. Population results of yeast-displayed ligands against CD276 and Thy1 using 
soluble extracellular domains. Binding specificity for each campaign was assessed by 
comparison to negative controls. Soluble Thy1-Fc or CD276 extracellular domains 
were used for positive selections (blue). Irrelevant proteins (human IgG for Thy1-Fc 
and streptavidin for CD276) were used as negative controls (orange). For detergent 
solubilized cell lysates and all cell panning methods, the MS1 transfectant that did not 
express the target of interest was used as a negative control. Target binding is shown 
in blue. Negative control binding is shown in orange. Note that the y-axes for the 
panning are different scales. 
The introduction of detergent solubilized cell lysate FACS as a translatable sort was 
largely not beneficial to isolation of target-specific binders (Figure 3-3). For both 
fibronectin domain evolution campaigns and affibody selected against Thy1, minimal 
separation is seen between populations sorted against target positive and target negative 
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lysates. Affibodies selected against CD276 did show one region where target specific 
binders appear to reside, but cross-reactivity appeared prevalently. 
 
Figure 3-3. Population results of yeast-displayed ligands against CD276 and Thy1 using 
soluble extracellular domains and detergent solubilized cell lysates. Detergent 
solubilized cell lysates of a target positive MS1 transfectant were used for selection 
(blue). For comparison, detergent solubilized cell lysates of the MS1 transfectant that 
did not express the target of interest was used as a negative control (orange). 
The introduction of cellular panning selections after enrichment on target-
conjugated magnetic beads allowed for isolation of cellular target specific binding in 
several cases (Figure 3-4). Fibronectin domains selected against CD276 showed a strong 
yield preference (3% vs. 0.3%) for MS1-CD276 cells relative to MS1-Thy1 cells after three 
additional rounds of selection. Affibodies selected against CD276 showed even stronger 
yield preference (7% vs. 0.1%) after only one round of additional selection. Insignificant 
yield preference was observed for fibronectin domains or affibodies selected against Thy1-
Fc. 
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Figure 3-4. Population results of yeast-displayed ligands against CD276 and Thy1 using 
cell panning methods. Monolayers of target positive MS1 transfectant were used for 
selection (blue). For comparison, monolayers of target negative MS1 transfectant 
were used as a negative control (orange). In the depleted panning case, recovery from 
the magnetic beads was also quantified (white and gray). 
3.4.2 Ligand Selections using Cell Panning Driven Methods 
Two cellular panning strategies were employed – one with magnetic bead 
depletions prior to enrichment on target-expressing cell monolayers and one with 
enrichment only (Figure 3-1). 
The enrichment-only selection strategy yielded strong enrichment of ligands after 
three rounds of selection in all cases (Figure 3-4). For fibronectin-based campaigns, yield 
preference was not observed for target expressing cells relative to target negative cells. 
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Weak yield preference was observed for both affibodies selected against MS1-Thy1 (2.6% 
vs. 2.0%) and MS1-CD276 (2.8% vs. 1.8%). 
Depletion selections using streptavidin-coated magnetic beads were employed as a 
facile way to potentially remove non-specific ligands. Unfortunately, the recovery of yeast 
from magnetic bead depletions was minimal across all campaigns and did not contribute to 
yield preference for target-expressing cells relative to target-negative cells after three 
rounds of selection (Figure 3-4). 
3.4.3 Cellular Target Specificity and Relative Binding Strength Characterization 
Characterizations of cellular target specificity and relative binding strength were 
carried out using a clonal cell panning microscopy assay (Figure 3-5A). Forty-eight clones 
from each sorted population were grown, induced, and allowed to bind to target expressing 
and target negative cells. Clones were characterized as “hits” if they bound target-
expressing cells and did not bind target-negative cells. Hits characterized in this way are 
highly likely to translate binding to cellular targets as soluble ligands given previous 
successes reported with an analogous 96-well plate screen57. The categories of “miss” were 
characterized: binding to both target-expressing and target negative cells (not specific for 
target of interest), binding only to target negative cells (counterspecific), and no binding to 
either target-expressing or target negative cells (non-binding). Binding strength was 
characterized by a relative count of yeast present in a microscope field (Figure 3-5B). 
Clones that specifically bound to target expressing cells were sequenced by Sanger 
sequencing to assess the diversity of the selected populations. 
Fibronectins selected against both soluble Thy1-Fc and CD276, as well as 
affibodies selected against Thy1-Fc, failed to yield any cell-binding ligands, with all 
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attempts falling into the non-binding category. In contrast, affibodies selected against 
soluble CD276 showed a hit rate of 47/48 with various binding strengths. This population 
also retained ample diversity with 3 unique sequences out of 5 taken. Similarly, when 
selections with detergent-solubilized cell lysates were added to soluble target selections, 
only affibodies selected against CD276 yielded hits, albeit with weaker relative binding 
strength than the analogous population selected with soluble target methods only. 
The addition of cellular selections to soluble target methods yielded hits from both 
the fibronectin (28/48) and affibody (41/48) populations selected against CD276. The 
fibronectin domains all bound weakly, and have converged on a single sequence while the 
affibodies retain their diversity of both binding strength and sequence (4/5 unique). Cellular 
selections were not able to salvage cell-binding activity from either the fibronectin or 
affibody populations selected against soluble Thy1-Fc. 
Selections for ligands using cell panning with magnetic bead depletion yielded hits 
for fibronectin against CD276 (3/48) as well as affibody against CD276 (4/48). These hits 
generally had weak to moderate binding strength with high sequence diversity. The major 
source of misses was a lack of desired target specificity, with all populations having at least 
20/48 that fell into this category. Similarly, direct cell panning without depletion yielded 
hits for affibody against both Thy1 (10/48) and CD276 (5/48). These populations generally 
showed weak to moderate binding, high sequence diversity, and a high frequency of 
undesired specificity. 
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Figure 3-5. Assessment of specificity for cellular target by yeast-displayed cell panning. 
Forty-eight individual clones from each sorted population were assessed for binding 
to target expressing and target negative MS1 cells by phase microscopy. Binding 
specificity, relative binding strength, and sequence diversity of specific binders were 
determined (A). Representative images of yeast displaying “-”, “+”, “++”, and “+++” 
clones are shown (B).   
3.5. Discussion 
High-throughput screening methods have facilitated the discovery of proteins 
capable of novel binding activity, but difficulties translating these interactions to cellular 
targets hampers progress in meeting clinical demands. The majority of ligand selection 
campaigns are carried out against purified soluble domains, which are not necessarily good 
models of their corresponding full length antigens, and can thus yield pools of binders with 
high affinity and specificity for the soluble domain but no activity toward the cellular 
antigen. Yeast surface display methods for direct cellular selections33,56,79 and 
fluorescence-activated cell sorting with detergent-solubilized cell lysates79,80 have been 
developed to sort for ligands with activity toward full length, cellular antigens, but the 
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efficacy of all of these methods for ligand development has yet to be directly compared. 
We sought to rigorously compare combinations of these five techniques using two different 
ligand libraries and two clinically relevant targets to determine the most efficient method 
for selection of proteins with specific activity toward cellular antigens. Cellular-based 
selection techniques proved to yield the highest frequency of successful campaigns. 
Campaigns conducted against only purified extracellular domains of Thy1 and 
CD276 failed to yield ligands that bound cellular antigens in three out of four cases. In all 
three failed campaigns, some level of non-specificity was observed at levels detectable 
with flow cytometry analysis. The Thy1 used in this study was an Fc fusion, and despite 
aggressive depletion with human IgG during magnetic bead selections, the presence of this 
tag allowed for the enrichment of clones that bind human IgG instead of their intended 
target (Figure 3-2). Interestingly, although it did not bind other reagents, the fibronectin 
population selected against CD276 also bound the soluble extracellular domain of MET 
(Figure 3-6), a target it had never been exposed to during sorting. These case studies 
illustrate the importance of both careful consideration in reagent selection and sort design, 
as incomplete depletion or depletion with irrelevant antigens can allow specificity 
problems to persist. In contrast, the affibody population sorted against soluble CD276 
returned a high frequency of diverse clones that specifically bound cellular CD276 with 
various binding strengths, suggesting that the CD276 used in this study contains some 
unknown number of translatable epitopes that could be accessed with the helical surface 
paratope library more efficiently than the loop paratope library. 
The addition of FACS with detergent-solubilized cell lysates after magnetic bead 
selections with soluble extracellular domains was not able to salvage translatable binding 
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ligands from any of the three failed campaigns (Figure 3-3 and Figure 3-5A). It is unclear 
whether lysate quality or target affinity prevented the isolation of a minority population of 
translatable binders in these selections. However, affibodies sorted against soluble CD276 
were able to be isolated from two rounds of FACS sorting, albeit with weaker binding 
strength than the corresponding population isolated by soluble target selection methods 
only. 
Direct cellular selections conducted after soluble target-based enrichment were able 
to enrich a single translatable clone from the fibronectin population selected against soluble 
CD276 (Figure 3-5A). This clone was likely a minority component in the bead sorted 
population as it was not isolated without cellular enrichment. However, its existence in the 
bead sorted population does confirm that at least one translatable epitope exists in the 
soluble CD276 extracellular domain that is accessible by a loop paratope. Cellular 
selections also isolated a wide variety of CD276-binding affibodies. Interestingly, none of 
the affibodies isolated from bead sorting followed by cellular selection showed sequence 
overlap with those isolated from soluble target methods alone. This likely has to do with 
the nature of the affinity-based FACS conducted prior to characterization of clones isolated 
with soluble target only. Unmodified cellular selections provide essentially no affinity 
pressure (Chapter 4), so affibodies isolated with this method likely fall in the population of 
clones with weaker affinity for both soluble and cellular CD276. Even cellular selections 
were not able to isolate cell-binding ligands from the fibronectin and affibody populations 
selected against soluble Thy1-Fc, suggesting that any translatable epitopes in this protein 
was not accessible by either paratope type. 
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Collectively, the use of cellular selections yielded successes in three out of four 
campaigns attempted. In contrast with the soluble domain-driven selection methods, which 
predominantly suffered from non-binders at the cellular level, the major source of “misses” 
for cellularly selected clones was non-specificity in all cases. Because the cell surface 
contains a wide array of macromolecules, including proteins, lipids, and polysaccharides, 
non-specific ligands have many options for binding partners. A subset of non-specific 
ligands potentially bind a specific antigen that is expressed on both target-expressing and 
target-negative cell lines. Others could bind macromolecules non-selectively through 
hydrophobic interactions, allowing them high avidity for enrichment on any cell type. In 
an attempt to deplete these non-specific binders, a set of campaigns utilized magnetic bead 
depletions prior to enrichment on mammalian cell monolayers. Population level 
quantification of recovery showed that this type of depletion was insufficient, recovering 
sub-1% quantities of yeast displaying non-specific ligands in all attempts (Figure 3-4). 
Indeed, when individual clones were assessed, the non-specificity problem persisted 
essentially identically to the case of cellular selection without depletion (Figure 3-5A). This 
result suggests that non-specificity has different characteristics depending on which 
selection method is used.  
3.6. Conclusion 
In conclusion, yeast-displayed cellular selections yield a higher frequency of 
campaigns yielding translatable binding ligands than methods driven primarily by soluble 
extracellular domain fragments. Ligands isolated from soluble extracellular domain-driven 
campaigns can yield surprising non-specificity despite aggressive depletion, and ultimately 
not translate to cellular binding. Cellular selections can be employed as a follow-up to the 
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use of soluble targets to enrich clones that bind translatable domains, but these are not 
present and accessible in all target-ligand pairings. Cellular selections also often lead to 
non-specificity that cannot be depleted using soluble target methods, but translatable, 
specific ligands can be isolated from clonal screening. A variety of promising fibronectin 
against CD276 and affibody ligands against Thy1 and CD276 have been isolated through 
these methods, which can be utilized for diagnostic and therapeutic benefit in future work. 
3.7. Supplemental Figures 
 
Figure 3-6. Assessment of specificity of fibronectin population against soluble CD276 
extracellular domain. The population of fibronectin domains selected by magnetic 
bead sorting against soluble CD276 extracellular domain was assessed for target 
specificity. The population was labeled by either 100 nM soluble CD276 extracellular 
domain (blue) or 100 nM soluble CMET extracellular domain (red). 
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Chapter 4 – Titratable Avidity Reduction Enhances Affinity 
Discrimination in Mammalian Cellular Selections of Yeast-
Displayed Ligands  
Adapted from:  Stern L.A., Csizmar C.M., Woldring D.R., Wagner C.R., and Hackel B.J.  
“Titratable Avidity Reduction Enhances Affinity Discrimination in Mammalian Cellular 
Selections of Yeast-Displayed Ligands.” Accepted by ACS Combinatorial Science, DOI: 
10.1021/acscombsci.6b00191. Copyright ACS Publications 2017. 
4.1. Abstract 
Yeast surface display selections against mammalian cell monolayers have proven 
effective in isolating proteins with novel binding activity. Recent advances in this 
technique allow for recovery of clones with even micromolar binding affinity. However, 
no efficient method has been shown for affinity based selection in this context. This study 
demonstrates the effectiveness of titratable avidity reduction using dithiothreitol (DTT) to 
achieve this goal. A series of epidermal growth factor receptor binding fibronectin domains 
with a range of affinities are used to quantitatively identify the number of ligands per yeast 
cell that yield the strongest selectivity between strong, moderate, and weak affinities. 
Notably, reduction of ligand display to 3,000 - 6,000 ligands per yeast cell yields 16-fold 
selectivity of a 2 nM binder relative to a 17 nM binder. These lessons are applied to affinity 
maturation of an EpCAM-binding fibronectin population, yielding an enriched pool of 
ligands with significantly stronger affinity than an analogous pool sorted by standard 
cellular selection methods. Collectively, this study offers a facile approach for affinity 
selection of yeast displayed ligands against full length cellular targets and demonstrates the 
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effectiveness of this method by generating EpCAM-binding ligands that are promising for 
further applications.  
4.2. Introduction 
A variety of engineered proteins have proven effective for molecularly targeted 
therapeutics5 and diagnostics1 for numerous disease states. The ever-growing landscape of 
clinically relevant cellular biomarkers motivates the continued development of new agents 
to diagnose and treat newly characterized conditions. 
To meet this demand, several high-throughput methods for selecting engineered 
proteins with novel binding functionality have been developed. One such method involves 
selections of yeast surface displayed ligands against mammalian cell monolayers56,79, 
which has been successfully implemented to isolate antibody fragments against brain 
endothelial cells57, B7-H458, and androgen-dependent prostate cancer59. Ligands 
discovered through this method are selected against full length, extracellularly-expressed 
transmembrane proteins, which differs from traditional selection methods using 
immobilized30,63 or fluorescently-labeled26 recombinant extracellular domains. Selections 
against recombinant extracellular domains can fail to translate to cellular binding for a 
variety of reasons, including the presence of unstable soluble domains43–46, incorrect post-
translational modification34,86, presence of biological or chemical tags38, or exposure of 
epitopes that would not be accessible in the full length protein. In some instances, results 
have been reported showing that a subset of clones isolated from selection campaigns using 
recombinant extracellular domains do not bind the full length, cellular target11,94. In more 
extreme instances, ligand selection campaigns relying on selection against recombinant 
extracellular domains can fail completely. However, as there is no good outlet for this 
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result, these difficulties are seldom reported, but nevertheless motivate the use of cellular 
proteins as targets for ligand selection. 
Recent advances to yeast-displayed cell panning allow for the recovery of ligands 
with even micromolar binding affinity33. While such modest affinities can be drastically 
improved by recursive mutagenesis95–98, an efficient cellular panning method has not yet 
been demonstrated for discrimination of higher affinity ligands from their weaker 
counterparts. One alternative method for affinity selection against full length 
transmembrane proteins is fluorescence activated cell sorting (FACS) with detergent 
solubilized cell lysates79,80,99. This method utilizes amphiphilic detergent molecules to 
stabilize the hydrophobic transmembrane domain, allowing these proteins to be used in 
selection in a concentration dependent manner. In cell panning, it has been shown that an 
8-fold decrease in the target expression of mammalian cells (from 1.5 ± 0.6x106 targets per 
cell to 1.9 ± 0.6x105 targets per cell) drastically decreases the recovery of weaker variants 
(17 ± 4 nM and micromolar affinity) while still allowing measurable recovery of a high 
affinity (2 ± 2 nM) clone in an epidermal growth factor receptor (EGFR) expressing 
system33. This suggests that the avidity between yeast and a mammalian cell is much less 
requisite to the recovery of stronger binding interactions. However, it is not always easy to 
generate cell lines with target expression ranging over several orders of magnitude. Further, 
expression variation cannot be achieved in cases where the biomarker’s identity is not 
known or where the target cells are not stably cultured (e.g. patient biopsy samples). The 
same study showed that decreasing the ligand expression of the yeast cell over a 3.5-fold 
range did not adversely affect recovery of either the 2 ± 2 nM or 17 ± 4 nM affinity variants. 
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However, the weakest protein expression tested was still near 10,000 ligands per yeast cell, 
which still has high avidity potential. 
 This study aims to determine if a further decrease in yeast valency can yield affinity 
discrimination in yeast-displayed cell panning selections. As ligands are tethered to the 
yeast surface by two disulfide linkages between yeast mating proteins agglutinin 1 (Aga1p) 
and agglutinin 2 (Aga2p), we demonstrate that controlled avidity reduction is achievable 
by titration with dithiothreitol (DTT). In a model system, we select mixtures of fibronectin 
domain clones with low nanomolar, mid nanomolar, and micromolar affinity for EGFR33 
against cancer cell monolayers expressing 1.5 ± 0.6x106 EGFR per cell to optimize the 
level of avidity reduction for preferential recovery of stronger binding interactions. Using 
this system, we show that a reduction from 8,000 ligands/cell to 3,000 - 6,000 ligands/cell 
is enough to observe a 16-fold enrichment advantage of a 2 nM binder relative to a 17 nM 
binder. However, a drastic decrease in avidity to 400 ligands/cell abolishes the ability to 
select, returning essentially the starting mixture composition. We then apply the lessons 
learned from this model system to the discovery and affinity selection of novel hydrophilic 
fibronectin domains engineered to bind epithelial cell adhesion molecule (EpCAM). 
 
4.3. Materials and Methods 
4.3.1 Cells and Cell Culture 
The MDA-MB-468 cell line was a kind gift from Professor Samira Azarin 
(University of Minnesota – Twin Cities). MCF-7, LnCAP, and U87 cell lines were 
purchased from ATCC. MDA-MB-468, MCF-7, and U87 cell lines were grown at 37 °C 
in a humidified atmosphere with 5% CO2 in Dulbecco’s modified Eagle’s medium with 
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4.5 g/L glucose, sodium pyruvate, and glutamine supplemented with 10% (v/v) fetal bovine 
serum and 1% (v/v) penicillin streptomycin. LnCAP cells were grown at 37 ºC in a 
humidified atmosphere with 5% CO2 in Roswell Park Memorial Institute (RPMI) medium 
with 4.5 g/L glucose, sodium pyruvate, and glutamine supplemented with 10% (v/v) fetal 
bovine serum and 1% (v/v) penicillin streptomycin. 
 Yeast surface display was performed essentially as described27. EBY100 yeast 
harboring expression plasmids were grown in SD-CAA medium (16.8 g/L sodium citrate 
dihydrate, 3.9 g/L citric acid, 20.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L 
casamino acids) at 30 °C with shaking at 250 rpm. Protein expression was induced by 
transferring yeast cells in logarithmic phase (OD600nm < 6) into SG-CAA medium (10.2 g/L 
sodium phosphate dibasic heptahydrate, 8.6 g/L sodium phosphate monobasic 
monohydrate, 19.0 g/L galactose, 1.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L 
casamino acids) and growing at 30 °C with shaking at 250 rpm for at least 8 h. EBY100 
without plasmid were grown in YPD medium (10.0 g/L yeast extract, 20.0 g/L peptone, 
20.0 g/L dextrose) at 30 °C with shaking at 250 rpm. 
 
4.3.2 Expression Plasmids 
The pCT-40 plasmid33 was used as the expression vector for yeast surface display. 
This vector encodes for Aga2p followed by an 80-amino acid linker – including a factor 
Xa cleavage site, an HA epitope, a 40-mer linker with two repeats of the PAS#1 peptide61, 
and a glycine-rich peptide – followed by the EGFR-binding fibronectin domain E6.2.6’ 
with a C-terminal MYC epitope. To enable facile analysis of clone mixtures by flow 
cytometry, the MYC epitope was replaced with either a V5 epitope or an E-tag epitope by 
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elongation PCR of an arbitrary gene followed by cloning into NheI and XhoI restriction 
sites, yielding pCT-40V and pCT-40E, respectively. Fibronectin domain E6.2.6’ N78S 33 
was cloned into pCT-40V by NheI and BamHI restriction sites. Fibronectin domain E6.2.6’ 
AASV33 was cloned into pCT-40E by NheI and BamHI restriction sites. 
 
4.3.3 Ligand Expression with DTT Titration 
5x106 yeast displaying fibronectin clone E6.2.6’ in pCT-40 vector were pelleted at 
8,000g and washed twice with 10 mM Tris buffer pH 7.5 (1.24 g/L Tris-HCl, 0.26 g/L Tris 
base). DTT was diluted to 0.5, 5, 10, 15, and 20 mM in 10 mM Tris buffer pH 7.5. Yeast 
were resuspended in 20 μL DTT solution and incubated at 30 °C for 20 min without 
shaking. Yeast were then pelleted at 8,000g and washed twice with PBSACM (PBS with 
1 g/L bovine serum albumin, 1 mM CaCl2, 0.5 mM MgCl2). To quantify relative ligand 
expression, yeast were labeled with 20 μL anti-MYC primary antibody (9E10, BioLegend, 
Cat: 626802, 5 μg/mL) for 20 min at room temperature, then washed once with PBSACM 
and pelleted at 8,000g for 1 min. Yeast were then labeled with 20 μL goat anti-mouse Alexa 
Fluor 647 conjugate (Thermo Fisher Scientific, Cat: A-21235, 10 μg/mL) and analyzed by 
flow cytometry using a BD Accuri C6. The average fluorescence of 10,000 events from 
each sample was compared to an untreated control. Events with fluorescence three standard 
deviations above the mean (<3%) were omitted from this analysis. 
To fully quantify the absolute expression of each ligand without DTT treatment, 
labeled yeast fluorescence was compared to a calibration curve prepared from anti-mouse 
IgG beads (Bangs Laboratories, Inc., Cat: 815). Polystyrene beads with known quantities 
of immobilized monoclonal anti-mouse IgG were labeled with 20 μL mouse anti-MYC 
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antibody (9E10, BioLegend, Cat: 626802, 5 μg/mL) and incubated for 20 min at room 
temperature. Beads were washed once with PBSACM and pelleted at 2,500g for 2.5 min. 
The beads were then labeled with 20 μL goat anti-mouse Alexa Fluor 647 conjugate (10 
μg/mL) for 20 min at room temperature. Beads were again washed with PBSACM and 
pelleted at 2,500g for 2.5 min. Concurrently, yeast expressing clone E6.2.6’ in pCT-40 
vector were labeled equivalently with mouse anti-MYC and goat anti-mouse Alexa Fluor 
647 conjugate as described above. Yeast expressing clone E6.2.6’ in pCT-40 vector, 
E6.2.6’ N78S in pCT-40V vector or E6.2.6’ AASV in pCT-40E vector were labeled 
concurrently with 20 μL goat anti-MYC FITC conjugate (Bethyl Laboratories, Cat: A190-
104F, 2 μg/mL), 20 μL goat anti-V5 FITC conjugate (Bethyl Laboratories, Cat: A190-
119F, 2 μg/mL), or 20 μL goat anti-E-tag FITC conjugate (Bethyl Laboratories, Cat: A190-
132F, 2 μg/mL) for 20 min at room temperature. Yeast were washed and pelleted at 8,000g 
for 1 min. Fluorescence was analyzed with a BD Accuri C6. The standard curve was 
compared to the fluorescence of the yeast that were labeled with the same mouse anti-MYC 
antibody and goat anti-mouse Alexa Fluor 647 conjugate. This expression level was 
mapped onto the other samples by comparison to the E6.2.6’ expressing yeast labeled with 
the goat anti-MYC FITC conjugate. 
Initial trials for yeast cell viability before and after DTT treatment were conducted 
using mixtures of approximately 1% pCT-40 E6.2.6’, 7% pCT-40V E6.2.6’ N78S, and 
92% pCT-40E E6.2.6’ AASV. Viability was assessed by dilution plating. 2x108 yeast were 
pelleted at 8,000g for 1 minute and washed twice with 10 mM Tris pH 7.5. As this point, 
viability prior to DTT treatment was assessed by dilution plating on YPD plates. Yeast 
were then treated with 800 μL 0, 2.5, 5, 10, or 15 mM DTT in Tris pH 7.5 at 30 °C for 20 
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min without shaking. Yeast were then pelleted at 8,000g and washed twice with PBSACM. 
Viability after DTT treatment was assessed by dilution plating on YPD plates. Additional 
trials were performed in essentially the same way, except 5x106 pCT-40 E6.2.6’ yeast were 
used, and the treatment volume was 20 μL to keep the same yeast:DTT ratio. 
 
4.3.4 Yeast Surface Display Cell Panning with Avidity Reduction 
Yeast mixtures of approximately 1% pCT-40 E6.2.6’, 7% pCT-40V E6.2.6’ N78S, 
and 92% pCT-40E E6.2.6’ AASV were generated and compositions were verified by flow 
cytometry analysis. Then, 2x108 yeast were washed twice with 10 mM Tris pH 7.5 and 
pelleted at 8,000g for 1 min. Yeast were resuspended in 800 μL 10 mM Tris buffer pH 7.5 
with 0, 2.5, 5, 10, or 15 mM DTT and incubated at 30 °C for 20 min without shaking, then 
washed twice with PBSACM and pelleted at 8,000g for 1 min.  
 MDA-MB-468 cells were grown to approximately 80% confluence in 12-well 
plates. Culture medium was removed via aspiration and cells were washed three times with 
500 μL ice cold PBSACM. Then, 5x107 yeast in 500 μL ice cold PBSACM were applied 
to MDA-MB-468 monolayers dropwise and incubated at 4 °C without shaking for 2 hours. 
Cells were washed 5 times with 500 μL PBSACM as described33. Briefly, cells were tilted 
25 times and rotated 5 times for the first four washes and rotated 10 times only for the fifth 
wash. SD-CAA media (500 µL) was added dropwise to each washed well, and cells were 
recovered by scraping. Recovered yeast were grown overnight in 5 mL SD-CAA at 30 °C 
with shaking at 250 rpm and protein expression was induced by transferring yeast into SG-
CAA media and incubating for at least 8 hours at 30 °C with shaking at 250 rpm. Clone 
composition is not expected to change due to propagation under non-induced conditions, 
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as previously shown for this vector family100. Final mixture compositions were determined 
by flow cytometry analysis using a BD Accuri C6, as described above. Compositions, 
enrichment ratios, and selectivities are reported as mean ± standard deviation of eight 
selections. 
 
4.3.5 Affinity Selection of EpCAM-Binding Engineered Fibronectin Domains 
EpCAM-binding fibronectin domains were selected via yeast surface display 
essentially as described27. Details regarding yeast cell growth and induction of ligand 
surface display are given above. Briefly, a yeast-display library of fibronectin domains32 
was subjected to negative selection against avidin-coated magnetic beads followed by 
magnetic beads functionalized with the irrelevant protein lysozyme to remove any non-
specific binding interactions. Remaining yeast were then exposed to magnetic beads 
functionalized with biotinylated recombinant human EpCAM (Acro Biosystems, Cat: 
EPM-H8223) and bound yeast were selected. Incubations were performed at 4 ºC and 
recovered beads were washed once in PBSA (PBS with 1 g/L bovine serum albumin) prior 
to culture in SD-CAA media at 30 ºC, 250 rpm for at least 12 hours. Protein induction was 
then induced as described above. 
After three rounds of magnetic selection, full-length (MYC positive) fibronectin 
clones were selected via FACS using mouse anti-MYC antibody (9E10, BioLegend, Cat: 
626802, 5 μg/mL) and goat anti-mouse Alexa Fluor 647 conjugate (Thermo Fisher 
Scientific, Cat: A-21235, 10 μg/mL). Isolated clones were subject to whole-gene and loop-
focused error-prone PCR using mutagenic nucleotide analogs92 and genetic loop shuffling 
between sequences67. After transformation of the mutants into EBY100 yeast, the resulting 
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population was subject to one additional round of magnetic selection at 4 ºC; recovered 
beads were washed twice with PBSA prior to culture in SD-CAA media at 30 ºC, 250 rpm 
for at least 12 hours. Ligand expression was induced as above. Yeast were then subject to 
two rounds of mammalian cell selections against adherent monolayers of the EpCAM-
overexpressing cell lines MCF-7 and LNCaP (Figure 4-5), as previously described33. Full 
length clones that bound biotinylated target, detected with a streptavidin Alexa Fluor 488 
conjugate (Thermo Fisher Scientific, Cat: S-11223, 10 µg/mL), were then isolated via 
FACS and diversified as before. 
After three additional rounds of panning against MCF-7 and LNCaP cell lines, 
target binding yeast were again isolated by FACS and diversified before panning against 
the same cell lines once more. This population was then subjected to three rounds of cell 
panning against MCF-7 cells in two parallel strategies: via the standard approach outlined 
above or with yeast valency reduction. In the case of the standard approach, yeast were 
panned against MCF-7 cells without DTT treatment.  For yeast valency reduction, yeast 
were treated with 2.5, 5, 7, and 9 mM DTT and washed as previously described. Valency 
was assessed by flow cytometry analysis with fluorescence standard beads and as 
previously described. The DTT treatment yielding a population with between 3,000 and 
6,000 ligands per yeast cell (often 2.5-5 mM, depending on the untreated level of protein 
expression) was used for selection. 
4.3.6 Protein Production and Analysis 
BL21(DE3) Escherichia coli (New England Biolabs, Cat: C2566I) were 
transformed with plasmid and grown overnight (37 ºC, 250 rpm) in lysogeny broth (LB) 
medium with kanamycin (50 µg/mL). Approximately 4 mL of overnight culture was added 
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to 100 mL LB medium without antibiotics, grown at 37 ºC, 250 rpm until the optical density 
at 600 nm (OD600) reached 0.65 – 1.0 (approximately 2 h), and induced with 1.0 mM 
isopropyl -D-1-thiogalactopyranoside (IPTG) for 3 h at 30 ºC, 250 rpm. Cells were 
pelleted (3,500g, 15 min, 4 ºC), frozen in a dry ice/ethanol bath, and resuspended in 8 mL 
SoluLyse protein extraction reagent (Genlantis Inc., Cat: L100125) supplemented with 
EDTA-free protease inhibitor (Thermo Fisher Scientific, Cat: 88266). Cell lysates were 
centrifuged (27,000g, 15 min, 4 ºC) to separate soluble and insoluble protein fractions, and 
the supernatant was filtered through a 0.22 µm membrane. Fibronectin domains were 
purified by immobilized metal affinity chromatography on a gravity column packed with 
HisPur cobalt resin (Thermo Fisher Scientific, Cat: 89964) following the manufacturer’s 
protocol, and eluted fractions were analyzed by SDS-PAGE. Fractions containing visibly 
pure fibronectin domains were pooled and buffer exchanged into phosphate buffered saline 
(PBS), pH 7.4, with Zeba spin desalting columns (Thermo Fisher Scientific, Cat: 89893). 
Protein concentration was determined via Bradford Protein Assay (Bio-Rad Laboratories, 
Cat: 500-0201) and diluted to 1 µM in additional PBS. Purified protein was analyzed by 
size-exclusion chromatography (SEC) on a Superdex 200 Increase 10/300 gel filtration 
column (GE Healthcare Life Sciences, Cat: 28990944) in PBS running buffer. Retention 
times of fibronectin domains were compared to those of commercial molecular weight 
standards (Sigma Aldrich, Cat: C7150 and C7025, respectively) cytochrome C (14.6 kDa) 
and carbonic anhydrase (29 kDa) and found to be ≥80% monomeric (Figure 4-8 and Figure 
4-9). 
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4.3.7 Affinity Titration of Fibronectin Domains 
MCF-7 cells were cultured to approximately 80% confluence, as described above. 
Detached MCF-7 cells were counted using a Countess II Automated Cell Counter. Aliquots 
of 40,000 MCF-7 cells were washed and labeled with varying concentrations of each 
fibronectin clone for 90 min at 4 °C with rotation. Cells were pelleted at 300g for 3 min 
and washed with 1 mL ice cold PBSACM, then labeled with 20 μL anti-His6 FITC 
conjugate (Abcam, Cat: ab1206, 13 μg/mL) for 20 min at 4 °C in the dark. Cells were again 
pelleted and washed with 1 mL ice cold PBSACM. Fluorescence was analyzed using a BD 
Accuri C6 or BD LSRII. 
 
4.4. Results and Discussion 
Yeast surface display selections against mammalian cell monolayers have shown 
success in the past, but their inability to preferentially select for high affinity ligands has 
been demonstrated. The lead published scFvs isolated using this method have affinities of 
82 ± 15 nM for rat brain endothelial (RBE4) cells57 and 27 ± 16 nM (determined 
multivalently) for androgen-dependent prostate cancer cells59. In both studies, numerous 
isolated scFvs required dimerization to assess binding character, suggesting clones with 
weaker affinities were isolated. Moreover, our aforementioned model system experiment 
yielded minimal differentiation of 2 ± 2 nM versus 17 ± 4 nM affinity33. Although 
functional for in vitro studies, preferential selection of stronger binders can aid in vivo 
imaging and therapeutic applications101. We sought to solve this by shifting from avidity-
driven interaction to affinity-driven interaction by decreasing yeast-displayed ligand 
expression in a controlled manner. 
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4.4.1 Effect of DTT Concentration on Yeast-Displayed Ligand Expression 
To determine the parameters to effectively tune ligand display levels, yeast 
expressing the EGFR-binding fibronectin domain E6.2.6’ in pCT-40 vector were subjected 
to 0 – 20 mM DTT concentrations for 20 min to reduce the Aga1p-Aga2p disulfide tether. 
Ligand display levels were assessed by flow cytometry analysis of untreated and treated 
yeast by labeling the C-terminal MYC tag. Ligand display levels were found to decrease 
in a titratable way with increasing DTT concentration (Figure 4-1A). Retention of 96 ± 
17%, 40 ± 19%, and 15 ± 14% of ligands was observed for 0.5 mM, 5 mM, and 10 mM 
DTT, respectively. As DTT is able to internalize and potentially reduce proteins essential 
to biological processes, yeast viability was also assessed by dilution plating prior to and 
after treatment (Figure 4-1B). Yeast remained at least 79 ± 17% viable for DTT 
concentrations up to 10 mM. Treatment with 15 mM DTT caused a viability decrease to 
67 ± 27% (though this decrease does not meet the typical level for statistical significance 
relative to the untreated case; p = 0.08). This knowledge allows for tuning of the ligand 
display level to satisfy the selection criteria needed. 
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Figure 4-1. The effect of DTT digestion on ligand display and yeast cell viability. Yeast 
displaying EGFR-binding fibronectin clone E6.2.6’ were subjected to DTT digestion 
at the indicated concentrations. (A) Relative fibronectin expression after DTT 
digestion was assessed by flow cytometry analysis of untreated and treated yeast by 
labeling the C-terminal MYC tag. Results are expressed as mean ± standard deviation 
of 4-5 trials. (B) Cell viability of yeast displaying E6.2.6’ or mixtures of E6.2.6’, 
E6.2.6’ N78S, and E6.2.6’ AASV after DTT treatment was assessed by dilution plating 
and is expressed as mean ± standard deviation of 5 trials. 
4.4.2 Selection of Fibronectin Domains with Reduced Avidity Against EGFR-Expressing 
Cells 
 The effect of reduced avidity on cellular selections was first evaluated in an EGFR-
expressing model system. Mixtures of yeast displaying previously characterized 
fibronectin domains with high-, mid- and low-affinity (2 ± 2, 17 ± 4, or >600 nM Kd, 
respectively33) for EGFR were treated with DTT and selected for binding to EGFR-
overexpressing MDA-MB-468 human breast cancer cells (1.5x106 EGFR per cell33) 
(Figure 4-2). Flow cytometry was used to determine the composition of the starting mixture 
prior to selection, and the resultant populations returned after cell panning. The starting 
mixture contained 1.4 ± 0.1% high-affinity (E6.2.6’), 6.8 ± 1.4% mid-affinity (E6.2.6’ 
N78S), and 92 ± 1.4% low-affinity (E6.2.6’ AASV) ligand expressing yeast (Figure 4-2A). 
Selection from this pool without DTT treatment (8,000 ligands per cell) yields 18 ± 5.8-
fold enrichment of E6.2.6’ and 12 ± 2-fold enrichment of E6.2.6’ N78S with strong 
disenrichment of E6.2.6’ AASV (Figure 4-2B). Although E6.2.6’ does significantly 
outperform E6.2.6’ N78S (p = 0.02) from an enrichment standpoint, the 1.6-fold selectivity 
improvement with strong affinity is not enough to expect higher affinity clones to overtake 
the population in an efficient number of selection rounds. Display reduction to 6,000 
ligands per cell (25% decrease) increases affinity discrimination drastically, yielding 
enrichment of 42 ± 2-fold for E6.2.6’ and 2.7 ± 0.4 for E6.2.6’ N78S (Figure 4-2B), 
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providing 16 ± 3-fold selectivity between high- and mid-affinity (Figure 4-2C). Further 
reduction to 3,000 ligands per cell (63% decrease) shows a similar result with 33 ± 8-fold 
enrichment for E6.2.6’ and 2 ± 0.3-fold enrichment for E6.2.6’ N78S (Figure 4-2B), 
retaining the 16 ± 5-fold advantage of high affinity (Figure 4-2C). Further display reduction 
to 1,000 ligands per cell reduces selectivity to 5.3 ± 1-fold.  At 400 ligands per cell, the 
system enters a regime where the ability to select becomes hindered, yielding a sorted 
composition that resembles the initial input (Figure 4-2A). In all cases, E6.2.6’ AASV is 
disenriched relative to the mid- and high-affinity ligands. 
 
 
Figure 4-2. The effect of reduced ligand expression on affinity selection against EGFR-
expressing mammalian cells. Yeast displaying fibronectin clones E6.2.6’, E6.2.6’ N78S, 
and E6.2.6’ AASV (affinities indicated33) were mixed and digested with the indicated 
amounts of DTT. Following DTT treatment, the ligand expression was quantitated by 
flow cytometry. DTT treated yeast were then panned against EGFR-positive MDA-
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MB-468 monolayers. (A) The mixture composition, (B) enrichment ratio for each 
clone , and (C) selectivity for E6.2.6’ relative to E6.2.6’ N78S  are indicated as the 
mean ± standard deviation of 8 selections with the exception of the initial mixture, 
which is the mean ± standard deviation of 4 mixtures. 
 
 The avidity between yeast and a mammalian cell is important to keep binding 
interactions intact throughout incubation, and to withstand the shear stress associated with 
washing the monolayer. The weak selectivity between E6.2.6’ and E6.2.6’ N78S without 
a reduction in the number of ligands on the yeast surface indicates that, within this affinity 
range, it is the high avidity between yeast and a mammalian cell that is driving recovery 
rather than ligand affinity . Reducing the number of ligands to between 3,000 and 6,000 
ligands per yeast cell increases the selectivity between these two clones because the 
diminished number of interactions between a yeast and mammalian cell causes ligand 
affinity to become more impactful in the ability of yeast to remain bound. Further reduction 
to 1,000 ligands per yeast cell shows a decrease in selectivity, as there is no longer enough 
avidity to reliably keep many of the yeast bound to mammalian cell. With extreme 
reduction to 400 ligands per yeast cell, the avidity between yeast and a mammalian cell is 
generally not strong enough to keep yeast bound through incubation and washing 
regardless of affinity, and thus essentially no selection is observed. These results suggest 
that while this method of affinity selection can yield coarse affinity discrimination, the 
level of discrimination is not likely to be as fine as fluorescence-activated cell sorting with 
soluble target36 or with detergent-solubilized cell lysate80 because the sort stringency of 
these techniques is tunable by simply drawing a strict sort gate. However, the ability to 
differentiate a 2 nM interaction from a 17 nM and a >600 nM interaction in these 
experiments is the first example of affinity discrimination with yeast surface display 
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against mammalian cell monolayers, a selection method that did not previously have any 
method for affinity discrimination. 
Not all ligands display at the same level. It should be noted that in these 
experiments, the ligands remaining per cell after DTT treatment, not the concentration of 
DTT used, is the most important metric for a successful selection. In the event that a ligand 
expresses at a level requiring greater than 10 mM DTT for the necessary level of ligand 
removal, other reducing agents with less cytotoxicity102, such as tris(2-
carboxyethyl)phosphine (TCEP), should be tested for efficacy and yeast viability. 
It should also be emphasized that not all ligands will be compatible with this 
selection. In particular, disulfide stabilized ligands such as antibody fragments or cystine 
knot peptides may exhibit detrimental conformational change due to destabilization from 
reduction. Yet, such changes could also serve to reduce functional valency, which could 
potentially achieve the same goal as Aga1p-Aga2p separation. Thus, the DTT reduction 
approach could still be used but DTT titration should be performed while acknowledging 
that disulfide reduction could impact both the Aga1p-Aga2p bonding and the ligand 
conformation. Alternatively, to achieve a more analogous avidity reduction for use with 
these ligands, digestion with factor Xa protease can be optimized to yield yeast with the 
appropriate number of ligands per yeast cell. A cut site for factor Xa protease is present in 
the yeast surface display linker N-terminal to the ligand. 
 
4.4.3 Affinity Maturation of EpCAM-Binding Fibronectin Domains 
  EpCAM is an attractive cancer target due to its overexpression in many different 
carcinomas including those of the breast, pancreas, esophagus, colon, and prostate103. 
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Many ligands have been evolved for EpCAM binding including antibodies and their 
fragments104, shark vNARs41, DARPins22,105, and small cyclic peptides42. Fibronectin 
domains12,87 have never been applied to EpCAM binding, but their evolvability for high 
affinity and specificity, small size, and ease of production and downstream handling could 
provide an advantage over established ligands. 
A population of EpCAM-specific fibronectin domains was selected through a 
combination of magnetic bead sorting and FACS sorting with soluble EpCAM 
extracellular domain and cellular based selection using MCF-7 and LnCAP cells. Three 
rounds of mutagenesis and selection were carried out to seek improved affinity. Clones 
isolated at this stage exhibited only moderate affinity for soluble EpCAM extracellular 
domain (Kd approximately 130-190 nM; Figure 4-6) and weak binding to EpCAM-
expressing human cell lines. Therefore, we sought to isolate higher affinity clones from the 
population via our avidity reduction approach. 
Three populations of EpCAM-binding fibronectin domains are compared: (1) an 
enriched pool of fibronectins obtained after three rounds of selection with avidity reduction 
(matured population with DTT), (2) a population from the same round of directed evolution 
sorted by standard cell panning methods (matured population without DTT), and (3) the 
population from the previous round of directed evolution (unmatured population). Soluble 
fibronectin domains from each population were produced as a polyclonal mixture and 
tested for binding to EpCAM positive MCF-7 cells (Figure 4-3A). For analysis of this data, 
binding is considered detectable for all events with fluorescence above the 95th percentile 
of the negative control. Binding is considered strong for events lying 2-fold above the 95th 
percentile of the negative control (Figure 4-3B). The unmatured population contains 15 ± 
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3% detectable binding events and 3 ± 1% strongly binding events. Upon mutagenesis and 
additional cell panning, the matured population distribution shifts to include more variants 
with stronger binding to MCF-7 cells, with 91 ± 4% of events detectable and 55 ± 11% 
appearing strong. When the mutated population is instead panned using yeast valency 
reduction with DTT, the resulting variants essentially all bind (99 ± 0.2% of events 
detectable) and are predominantly strong binders (89 ± 6%). Significantly more strong 
binders are found in the matured population panned using yeast valency reduction than the 
matured population panned without DTT treatment (p = 0.02). To further examine this 
difference in affinity, individual clones from each population were selected based on 
differences observed in individual sequences obtained from Sanger sequencing of random 
clones. A subset of these clones were produced as soluble, monoclonal domains and 
purified. Affinities of these clones were determined by flow cytometry (Figure 4-3C). The 
affinities of clones isolated from the matured population with DTT (median: 24 nM) were 
significantly higher (p = 0.04) than those of clones isolated from the matured population 
without DTT (median: 1,600 nM). Furthermore, these higher affinity clones are 
comparable to a commercially available monoclonal antibody known to target EpCAM 
(clone 9C4) when tested in parallel in a flow cytometry based cell binding assay (Figure 4-
7). Importantly, none of the tested clones with strong affinities bind appreciably to EpCAM 
negative U87 cells (Figure 4-3D)106,107. While all isolated clones appear to be from the 
same family based on upstream convergence of the lead polypeptide, four out of five of the 
clones tested from the matured population with DTT show a P87L/S mutation that may be 
beneficial for stronger binding (Figure 4-4). This mutation could allow for increased 
flexibility directly C-terminal to the engineered FG loop, enabling a more favorable 
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conformation of the loop. Alternatively, the L/S residue itself may directly contribute as 
part of the binding paratope as loop-adjacent residues have been shown to in the 
past67,108,109. This structure-function determination is beyond the scope of this study, and 
thus was not interrogated further. 
 
Figure 4-3. Characterization of EpCAM-binding fibronectin populations and individual 
clones. (A) Polyclonal populations of soluble EpCAM-binding fibronectin domains 
were assessed for relative affinity against EpCAM-expressing MCF-7 cells at 10 nM 
via flow cytometry. (B) Quantitative analysis of the flow cytometry experiments was 
performed. For this analysis, the percentage of fluorescent events appearing above 
the 95th percentile (“binding events”) and 2-fold above the 95th percentile (“strongly 
binding events”) of the negative control were quantified as mean ± standard error of 
8 trials. (C) Individual fibronectin clones were produced solubly, and their affinity 
towards EpCAM-expressing MCF-7 cells was determined by flow cytometry. 
Affinities are presented as mean ± standard error of 2-5 trials (instances where only 
two trials were performed are presented as mean ± range). (D) The same soluble 
fibronectin clones were assessed for binding against EpCAM-negative U87 cells at 
100 nM via flow cytometry to determine the specificity of these clones. Clones are 
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named with letters corresponding to the population from which they were isolated: 
“A” denotes clones isolated from the unmatured population, “B” denotes clones 
isolated from the population matured without DTT, and “C” denotes clones isolated 
from the population matured with DTT. The coloring of clone names further 
represents their parent population, akin to Figures 3A and 3C. Median fluorescence 
intensities are presented as mean ± standard error of 2-5 trials (instances where only 
two trails were performed are presented as mean ± range). All samples include U87 
(EpCAM-negative) data, but most U87 bars (white) are not visible because of their 
near-zero fluorescence after background correction. 
  The knowledge gained from the aforementioned experiments allows for tuning 
yeast-displayed cellular selections to preferentially recover higher affinity ligands in a 
robust, facile way without the need of decreasing target expression on the mammalian cells. 
This is in contrast to previous work, where fluorescein-binding scFvs were panned against 
RBE4 cells labeled with increasing amounts of FITC56 and EGFR-binding fibronectin 
domains were panned against various breast cancer cell monolayers with varying EGFR 
expression levels33. This is especially important for affinity maturation of engineered 
ligands because, after mutagenesis, it is expected that an overwhelming majority of ligands 
either retain or decrease their binding affinity while only a small percentage actually 
improve110,111. The ability to modify yeast-displayed cellular selections for the enrichment 
of this small percentage of improved clones ensures that ligands can be selected against 
full length, cellular target molecules. This avoids the use of established affinity 
discrimination methods that use soluble extracellular domains36 or detergent solubilized 
cell lysates80, which may not be available or may not translate to affinity maturation against 
genuine cellular target. 
Additionally, though not shown in this work, the methods developed in this study 
could be applied directly to naïve ligand libraries for the initial rounds of selection in an 
attempt to isolate the highest affinity binders present in the initial pool. The success of 
these selections would depend on the initial library quality; ligands isolated from 
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engineered libraries that have not yet undergone affinity maturation often have weak 
affinity67, though this is not always the case32. In the situation where the number of high 
affinity binders in the initial pool is diminishingly small, selection under conditions of 
reduced avidity will likely fail and is not recommended. Conversely, if a robust library is 
employed, then the avidity reduction approach may expedite the overall directed evolution 
process by enriching the high affinity binders at a much earlier round of selection. 
 
 
Figure 4-4. Sequences for EpCAM-binding fibronectin domains. Sequences of 
EpCAM-binding fibronectin domains were compared by sequence alignment. 
Residues that match consensus are denoted by a ●. Engineered loop residues are 
shown in bold. P87L/S mutation is highlighted in red. Clones are labeled with letters 
corresponding to the population from which they were isolated: “A” denotes clones 
isolated from the unmatured population, “B” denotes clones isolated from the 
population matured without DTT, and “C” denotes clones isolated from the 
population matured with DTT. 
 
4.5. Conclusions 
 In conclusion, yeast-displayed cellular selections can be modified for affinity 
discrimination by decreasing ligand expression with DTT treatment, as ligand expression 
decreases titratably with increased concentration of DTT. In an EGFR model system, 
reducing the number of displayed ligands to 3,000 – 6,000 per cell allowed for 16-fold 
selectivity of a high-affinity (2 nM) binder relative to a mid-affinity (17 nM) ligand. 
However, further reduction in ligand expression decreased the overall effectiveness of 
selection. These considerations were applied to the affinity maturation of EpCAM-binding 
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fibronectin domains, where a small percentage of clones had a stronger target affinity than 
the majority of the pool, but selection was not possible using standard protocols. When 
applied to this experimental system, cell panning selections augmented with avidity 
reduction enabled the isolation of novel fibronectin clones with significantly improved 
affinity for cellular EpCAM. These findings should ultimately increase the success of 
ligand engineering by aiding the isolation of strongly functional proteins that interact with 
full length cellular target. 
4.6. Supplemental Figures 
 
Figure 4-5. EpCAM expression of MCF-7 and LnCAP cells. The EpCAM expression 
levels of MCF-7 and LnCAP cells lines were quantified via flow cytometry by 
comparing the mean fluorescence intensities to a calibration curve (generated by 
concurrently staining and analyzing known calibration beads). MCF-7 cells were 
found to have approximately 7.9x105 EpCAMs per cell. LnCAP cells were found to 
have approximately 2.7x105 EpCAMs per cell. 
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Figure 4-6. Affinity estimations for intermediate anti-EpCAM fibronectin clones.  The 
affinity of yeast-displayed clones from the population matured without DTT towards 
soluble EpCAM ectodomain was assessed via flow cytometry. Apparent dissociation 
constants (KD) were estimated by fitting the mean fluorescence intensity values to a 
nonlinear regression model assuming a single binding site. (A) Clone 3.2.20 was 
titrated twice, and the KD value is shown as the mean ± standard deviation of the two 
independent trials. (B) All other clones were titrated only once, and are portrayed as 
estimates without error. Estimated KD values ranged from 125.6 nM to 189.7 nM. 
Notably, no clones possessed measurable affinity for the irrelevant soluble CD3 
ectodomain. 
 
Figure 4-7. Comparison of Anti-EpCAM Fibronectin Clones and Monoclonal Antibody 
9C4. Soluble anti-EpCAM fibronectin clones were evaluated for their ability to 
saturate EpCAM+ MCF-7 cells via flow cytometry. As a positive control, an anti-
EpCAM monoclonal antibody (clone 9C4) was evaluated simultaneously. (A) MCF-7 
cells were saturated with either a soluble fibronectin clone or with 9C4 at 100 nM. 
Shown is a representative composite histogram of the fluorescence intensities 
produced by each sample in a single trial. (B) The analysis was performed in 
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triplicate, and the mean fluorescence intensities produced by each clone are shown. 
Data is presented as the mean ± standard deviation of the three independent trials. 
 
Figure 4-8. Characterization of soluble fibronectin clones by size exclusion 
chromatography. Soluble fibronectin domains were produced, buffer exchanged into 
PBS, and diluted to 1 µM as described in the main text. SEC analyses were performed 
on a Dionex UltiMate 3000 UHPLC (Thermo Scientific) equipped with a Superdex 
200 Increase 10/300 gel filtration column (GE Healthcare Life Sciences) by injecting 
80 µL of the 1 µM protein solution; phosphate buffered saline (PBS), pH 7.4, was used 
as running buffer. Data analysis was performed in the associated Chromeleon 7 
software package (Thermo Fisher Scientific), and peak integration confirms that all 
clones are ≥80% monomeric. One representative clone from each population 
(unmatured in magenta; matured without DTT in maroon; matured with DTT in 
green) is compared to the commercial molecular weight standards cytochrome C 
(14.6 kDa, blue) and carbonic anhydrase (29.0 kDa, black) (Sigma Aldrich). 
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Figure 4-9. Characterization of soluble fibronectin populations by size exclusion 
chromatography. Soluble fibronectin domains were produced, buffer exchanged into 
PBS, and diluted to 1 µM as described in the main text. SEC analyses were performed 
on a Dionex UltiMate 3000 UHPLC (Thermo Scientific) equipped with a Superdex 
200 Increase 10/300 gel filtration column (GE Healthcare Life Sciences) by injecting 
80 µL of the 1 µM protein solution; phosphate buffered saline (PBS), pH 7.4, was used 
as running buffer. Data analysis was performed in the associated Chromeleon 7 
software package (Thermo Fisher Scientific), and peak integration confirms that the 
populations are comprised of ≥80% monomers. The three soluble fibronectin 
populations were compared to each other (unmatured in magenta; matured without 
DTT in black; matured with DTT in blue) and to the same commercial molecular 
weight standards as before (see Figure 4-8). 
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Chapter 5 – Depletion Aids Isolation of Target-Specific, 
Translatable Binding Interactions in Mammalian Cellular 
Selections of Yeast-Displayed Ligands 
5.1. Abstract 
Mammalian cellular selections with yeast surface displayed ligands have yielded 
ligands with novel binding activity. Unfortunately, ligands that bind without molecular 
specificity enrich from naïve library selections in high frequency. There is currently no 
efficient method for depletion of these non-specific binding ligands in this system. This 
study aims to determine an appropriate method for non-specific binder depletion using 
CD276-specific, non-specific, and non-binding affibodies. Calculation of theoretical 
results based on literature data suggest that sequential depletion against adhered 
mammalian cell monolayers would effectively remove non-specific binding ligands, but 
experimental results show inconsistencies in the selectivity of this scheme. Instead, a pre-
blocking strategy using disadhered mammalian cells yields a 14-fold selectivity for a high-
yield CD276-specific binder relative to a high-yield non-specific binder. This method can 
be directly applied to selections from naïve ligand libraries to decrease the frequency of 
non-specific binding clones isolated. 
5.2. Introduction 
Ligand selections against mammalian cell monolayers have yielded novel binding 
proteins against multiple targets utilizing both yeast surface display57–59 and phage display 
approaches47. Often, these selections are carried out without a step intended to deplete non-
specific binding ligands, allowing any protein with activity toward the cell line of interest 
to enrich. This often leads to the isolation of both target specific and promiscuous ligands 
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49,59,69. The phage display community has moved to solve this problem either by depletion 
against target-negative mammalian cell monolayers112, depletion against target-negative 
disadhered mammalian cells51, or blocking with the soluble form of non-specific ligands 
isolated from the library used in selection113. However, no much method currently exists 
for yeast surface display selections against mammalian cell monolayers. 
Recent work completed in Chapter 3 of this dissertation echoes the findings of the 
community. Selections from both a fibronectin domain32 and an affibody (Daniel Wolding, 
Patrick Holec, LAS, Yang Du, and Benjamin Hackel, unpublished) library without 
depletion yielded a high frequency of non-specific binding ligands. Further, selections 
against the same cell lines employing depletion steps using magnetic beads coated with 
irrelevant antigens were unable to decrease the frequency of non-specific ligands isolated. 
This phenomenon implies that the mechanism of non-specificity in the cellular selection 
context is not solely protein driven, but likely involves other macromolecules, including 
polysaccharides and lipids. 
In order to properly deplete these non-specific ligands, a method for depletion that 
efficiently screens these interactions against target-negative mammalian cells is needed. 
This work aims to optimize non-specific ligand depletion against target-negative 
mammalian cells with yeast surface display in a CD276-expressing model system. Both 
sequential depletion against mammalian cell monolayers and pre-blocking with disadhered 
mammalian cells are tested. Although a simple mathematical model of sequential depletion 
against mammalian cell monolayers suggests improved depletion of non-specific ligands 
as the number of depletion steps is increased, experimental results show that depletion in 
this context is stochastic and thus not a robust solution. Instead, pre-blocking with 
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disadhered target-negative mammalian cells shows a robust 14-fold selectivity of a specific 
binder relative to the no depletion case. This method for depletion of non-specific binding 
ligands can be applied to naïve library sorting starting from the first round of selection to 
decrease the frequency of non-specific ligands recovered. 
5.3. Materials and Methods 
5.3.1 Cells and Cell Culture 
MS1-CD276 and MS1-Thy1 cells were a kind gift from Professor Jurgen K. 
Willmann (Stanford University). Cells were grown at 37 °C in a humidified atmosphere 
with 5% CO2 in DMEM with 4.5 g/L glucose, sodium pyruvate, and glutamine 
supplemented with 10% (v/v) fetal bovine serum. 
Yeast surface display was performed essentially as described27. EBY100 yeast 
harboring expression plasmids were grown in SD-CAA medium (16.8 g/L sodium citrate 
dihydrate, 3.9 g/L citric acid, 20.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L 
casamino acids) at 30 °C with shaking. Protein expression was induced by transferring 
yeast cells in logarithmic phase (OD600nm<6) into SG-CAA medium (10.2 g/L sodium 
phosphate dibasic heptahydrate, 8.6 g/L sodium phosphate monobasic monohydrate, 19.0 
g/L galactose, 1.0 g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L casamino acids) and 
growing at 30 °C with shaking for at least 8 h. 
 
5.3.2 Expression Plasmids 
The pCT-40 plasmid33 was used as the expression vector for yeast surface display. 
This plasmid encodes for Aga2p, an 80-amino acid linker (40 amino acids longer than the 
conventional pCT yeast display construct), an affibody domain, and a C-terminal MYC 
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epitope. For facile analysis of clone mixture compositions by flow cytometry, two other 
versions of this vector have been made which swap the MYC epitope with a V5 epitope 
(pCT-40V) or an E-tag epitope (pCT-40E) (Chapter 4). 
CD276-specific or non-specific affibody clones were chosen from populations 
selected to bind either soluble CD276 extracellular domain or MS1-CD276 cells with 
relative binding strength defined with a phase microscopy assay (Chapter 3). CD276-
specific affibody clones HS (high-yield specific) and LS (low-yield specific) were cloned 
into pCT-40 vector by NheI and BamHI restriction sites. Non-specific affibody clones HN 
(high-yield non-specific) and LN (low-yield non-specific) were cloned into pCT-40V 
vector by NheI and BamHI restriction sites. Non-binding affibody clone A533 was cloned 
into pCT-40E vector by NheI and BamHI restriction sites. 
 
5.3.3 Determination of Optimal Incubation Time for Cellular Selections 
MS1-CD276 were grown to approximately 90% confluence in 12-well plates. 
Culture medium was removed and cells were washed three times with 500 μL ice cold 
PBSACM (PBS with 1 g/L bovine serum albumin, 1 mM CaCl2, 0.5 mM Mg2SO4). 
5x107 yeast expressing CD276-specific affibody clone HS or LS were pelleted at 
8,000g for 1 min, washed once with ice cold PBSACM, and resuspended in 500 μL ice 
cold PBSACM. Yeast were then applied to MS1-CD276 monolayers dropwise and 
incubated at 4 °C without shaking for 15 min, 30 min, 45 min, 60 min, or 120 min. Cells 
were washed 5 times with 500 μL ice cold PBSACM as described33. Briefly, cells were 
tilted 25 times and rotated 5 times for the first four washes and rotated 10 times only for 
the fifth wash. 500 μL SD-CAA was added dropwise to the washed wells, and cells were 
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recovered by scraping. Yeast recovery was quantified by dilution plating on YPD plates 
(10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, 16 g/L agar). 
 
5.3.4 Depletion of Non-specific Clones with Sequential Depletion 
Mixtures 0.2 ± 0.1% CD276-specific, 3 ± 2% non-specific, and 97 ± 2% non-
binding affibody-displaying yeast were generated and compositions were quantified by 
flow cytometry analysis. Yeast were pelleted and washed once with ice cold PBSACM, 
then resuspended to a concentration of 1x108 yeast/mL in ice cold PBSACM. 
MS1-Thy1 and MS1-CD276 were grown to approximately 90% confluence in 12-
well plates. Culture medium was removed and cells were washed three times with 500 μL 
ice cold PBSACM. 500 μL of yeast mixture were added to MS1-Thy1 monolayers 
dropwise and incubated at 4 °C for 15 min without rotation. The binding buffer containing 
unbound yeast was collected. Monolayers were washed 4 times as described in the previous 
section, with unbound yeast collected and pooled. The collected yeast were concentrated 
into 500 μL ice cold PBSACM and applied to the next washed MS1-Thy1 monolayer. This 
process was repeated for 0, 2, 4, or 6 depletion steps against MS1-Thy1 monolayers. 
Recovered yeast were then applied to an MS1-CD276 monolayer and incubated at 4 °C for 
120 min. Monolayers were washed 5 times, and bound yeast were recovered by scraping 
as before. Yeast recovery was quantified by dilution plating on YPD plates. Recovered 
yeast were grown in 5 mL SD-CAA at 30 °C with shaking. Protein expression was induced 
by resuspending a portion of the outgrowth in SG-CAA at OD600nm<1 and growing these 
yeast for at least 8 hours at 30 °C with shaking. 
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Mixture compositions were quantified by flow cytometry analysis. Yeast were 
pelleted and washed once with 1 mL PBSACM. Yeast were then labeled with 20 μL goat 
anti-c-myc FITC conjugate (Bethyl Laboratories, Cat: A190-104F, 2 μg/mL), goat anti-V5 
FITC conjugate (Bethyl Laboratories, Cat: A190-119F, 2 μg/mL), or goat anti-E-tag FITC 
conjugate (Bethyl Laboratories, Cat: A190-132F, 2 μg/mL) for 20 min at room 
temperature. Yeast were then pelleted and washed once with PBSACM. Fluorescence was 
analyzed using an Accuri C6 (BD Biosciences). 
 
5.3.5 Depletion of Non-specific Clones by Pre-Blocking with Disadhered Mammalian 
Cells 
MS1-Thy1 were grown to approximately 90% confluence in a T-75 cell culture 
flask. Culture medium was removed and cells were washed once with 5 mL PBS. Cells 
were disadhered by trypsin-EDTA treatment for 6 min, then quenched by the addition of 
serum-containing culture medium. Cells were then pelleted at 500g for 3 min, trypsin-
containing culture medium was removed, and cells were resuspended in fresh culture 
medium for counting using a Countess II FL (Thermo Fisher Scientific). 
Mixtures of 0.3 ± 0.1% CD276-specific, 1.9 ± 0.8% non-specific, and 98 ± 0.7% 
non-binding affibody-displaying yeast were generated and compositions were quantified 
by flow cytometry analysis. Yeast were pelleted and washed with ice cold PBSACM and 
resuspended to 5x107 yeast in 500 μL ice cold PBSACM containing 1x106 MS1-Thy1. 
Yeast and MS1-Thy1 were incubated at 4 °C with rotation for 2 hours. After incubation, 
samples were added dropwise to washed MS1-CD276 monolayers in 12-well plates and 
incubated at 4 °C without rotation for 15 min. Monolayers were washed five times with 
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500 μL ice cold PBSACM as described above. Bound yeast were recovered by scraping. 
Yeast recovery was quantified by dilution plating on YPD plates. Recovered yeast were 
grown, protein expression was induced, and final mixture composition was determined as 
described above. 
 
5.4. Results and Discussion 
5.4.1 Mathematical Modeling of Sequential Depletion Against Adhered Cells 
To aid the design of depletion experiments, a simple mathematical model for 
enrichment of yeast against mammalian cell monolayers was employed (Figure 5-1). The 
initial step of this model involves the co-enrichment of specific and non-specific ligand 
expressing yeast against target positive cells (Figure 5-1A). The starting pool was 1 ppm 
specific binder, 25 ppm non-specific binder, and the balance non-binder. Based on 
experimental parameters determined in previous work, the yield of a binder against target 
positive cells was 25%, and the yield of a non-binder was 0.5%33. Although the specific 
and non-specific binders have the same yield fraction, the 25-fold higher starting point for 
the non-specific binders allows them to dominate the population (74%) after three rounds 
of enrichment while the specific binders are only present at 3%. This modeled behavior is 
reflected well by experimental enrichment of ligands from fibronectin domain and affibody 
libraries against two different target cell lines, which yielded 0-20% target specific binders 
and 38-98% non-specific binders after three rounds of enrichment (Chapter 3). Additional 
enrichment in the model system yields a population containing 96% non-specific binders, 
4% specific binders, and essentially 0% non-binders after five rounds of selection. 
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In an attempt to decrease the frequency of non-specific binders, three depletion 
schemes were modeled. The starting population for depletion was the mixture yielded from 
the third round of enrichment. First, a sequential depletion approach against target negative 
cells was modeled (Figure 5-1B). For this system, specific binders and non-binders have a 
yield of 0.5% and non-specific binders have a yield of 25% with the balance being taken 
forward to subsequent rounds of depletion. After 12 rounds of depletion, specific binders 
(11%) overtake non-specific binders (9%). However, non-binders dominate the population 
given their relatively high abundance in the starting pool. Non-specific binders are 
abolished from the population after 23 rounds of depletion. Overall, this scheme does 
accomplish the goal of depleting non-specific binders, but the inability to deplete non-
binders necessitates the addition of enrichment steps against target positive cells to confer 
a yield advantage to target specific binders. 
Thus, a depletion scheme with the addition of a single enrichment step after 
depletion step 6 was modeled (Figure 5-1C). In this strategy, the proportion of non-binding 
ligands decreases from 58% to 3% after the enrichment step. Specific binders (50%) 
overtake non-specific binders (42%) after 13 rounds of selection. Similar results are 
observed when this scheme is modeled with a single enrichment after depletion step 12 is 
added (Figure 5-1D). Based on these results, a sequential depletion approach with 
enrichment steps interspersed appears able to allow for depletion of non-specific binding 
ligands. 
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Figure 5-1. Model of enrichment and depletion schemes against adhered mammalian 
cells. A mixture of specific, non-specific, and non-binding ligands were modeled for 
enrichment against target positive cells (A). The mixture obtained after three rounds 
of enrichment was modeled in three depletion schemes against target negative cells: 
sequential depletion only (B), sequential depletion with an enrichment step against 
target positive cells after step 6 (C), and sequential depletion with an enrichment step 
against target positive cells after step 12 (D). The model assumes that the starting 
mixture contains 1 ppm specific ligand, 25 ppm non-specific ligand, and the balance 
non-binding ligand. Binding ligands are recovered with 25% yield. Non-binding 
ligands are recovered with 0.5% yield. The starting mixture for the three depletion 
schemes corresponds to three enrichment steps from Figure 5-1A. 
Sensitivity analysis on this model shows how selection outcomes differ as the yields 
of both specific and non-specific binders are modulated simultaneously from 5-30% 
(Figure 5-2). For the enrichment only scheme, the proportion of specific binders present in 
the mixture after three enrichment steps shows only small variation, ranging from 0-3% 
while the proportion of non-specific binders increases drastically from 2-82% (Figure 5-
2A). When sequential depletion without enrichment is carried out, the composition of 
specific binder ranges from 0-17% while the non-specific binder composition peaks at 2% 
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for a yield of 10% (Figure 5-2B). The addition of an enrichment step during sequential 
depletion does not change the final result regardless of when the enrichment occurs (Figure 
5-2C,D). In both cases, the proportion of specific binder ranges from 1-91%. The 
proportion of non-specific binder shows the expected decreasing trend on the yield range 
of 10-30%, but decreases again with 5% yield. This is likely due to a combination of the 
low yield and the small starting quantity (2%). 
 
Figure 5-2. Sensitivity analysis on modeled enrichment and depletion schemes. The 
yield of binder was modulated from 5-30% for each scheme modeled in Figure 5-1. 
Composition of pure enrichment against target positive cells is modeled after three 
enrichment steps (A). Sequential depletion only (B), sequential depletion with 
enrichment after step 6 (C), and sequential depletion with enrichment after step 12 
(D) are modeled after 24 total steps. The starting point for each depletion scheme is 
the composition shown in Figure 5-2A with the corresponding yield. 
5.4.2 Determination of Optimal Incubation Time 
Based on the model results, many rounds of sequential depletion are required to 
successfully deplete non-specific binding clones. Unfortunately, the previously 
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demonstrated effective incubation time for cellular selections is two hours33,79, which limits 
the number of sequential depletion steps that can be completed in a day. However, it has 
never been shown that this incubation time is optimal. To determine if there is a lower 
effective incubation time, affibody clones HS and LS were enriched against MS1-CD276 
for 15, 30, 45, 60, or 120 min. Both clones showed yields that were essentially invariant 
with time, with the slope of the recovery versus incubation time plot being essentially zero 
in both cases. Affibody clone LS yielded 8 ± 3% for a 15 min incubation and 9 ± 5% for a 
120 min incubation time (Figure 5-3A). These results were not significantly different 
(p=0.6). Affibody clone HS yielded 10 ± 4% with a 15 min incubation and 16 ± 7% for a 
120 min incubation time, which is significantly different (p=0.04) (Figure 5-3B). However, 
given the similar yield range and the strong advantage of being able to perform eight times 
more selection steps in a day with a shorter incubation time, 15 min was the chosen duration 
for depletion steps for the remainder of the study. 
 
Figure 5-3. Optimization of incubation time for yeast-displayed ligand enrichment. 
Yeast displaying affibody clones LS (A) or HS (B) were incubated with MS1-CD276 
for varying incubation times. Recoveries are presented as the mean ± standard 
deviation of 7-12 trials.  
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5.4.3 Sequential Depletion of non-specific binders against adhered mammalian cells 
To experimentally investigate the model of sequential depletion, mixtures of 
CD276-specific, non-specific, and non-binding ligands were sorted by depleting with 0, 2, 
4, or 6 sequential exposures to MS1-Thy1 cells followed by an enrichment step against 
MS1-CD276 (Figure 5-4). For the mixture of high-yield binders (clones HS, HN, and A5), 
the 0 depletion case yielded nearly identical enrichment ratios for clones HS (24 ± 20) and 
HN (29 ± 7) (p=0.7). The use of sequential depletion steps does, on average, confer an 
enrichment advantage to clone HS relative to clone HN (Figure 5-4A), but the trends are 
surprising. As additional depletion steps are added, the enrichment ratio of both clones HS 
and HN remain essentially unchanged. However, it is difficult to draw conclusions from 
this data set because the enrichments are inconsistent. For example, the average enrichment 
ratio of clone HS with 2 depletion steps is 140 ± 130. The enrichment ratios that yield this 
average are 220, 260, 270, 24, 20, and 17. Importantly, the final three trials listed essentially 
match the average enrichment ratio of clone HN under this condition (24 ± 2), suggesting 
that there is no advantage conferred to clone HS despite the two depletion steps. Results 
using the low-yield binder mixture (LS, LN, and A5) shows similar inconsistencies (Figure 
5-4B). In all cases, non-binding ligands are strongly disenriched. 
The inconsistent enrichment of target specific binders from these mixtures could be 
a result of non-specific yeast-mammalian cell interactions that are not ligand mediated or 
sequestration of yeast in the corners of the plate wells. It is known from previous studies 
that there is a baseline level of background recovery of approximately 0.1% of the yeast 
input (Chapter 2). Loss of the rare CD276-specific yeast through this mechanism would be 
impactful on their ability to be recovered. This effect is compounded through each 
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additional depletion step, potentially explaining the generally decreasing trend in 
enrichment of CD276-specific binders as more depletion steps are added. It is unclear, 
however, why the enrichment ratio of the non-specific binding yeast remains essentially 
unchanged with increasing depletion. It is possible that the yield of non-specific binder 
against target negative cells may have been lower than expected, disfavoring depletion as 
predicted by the sensitivity analysis of the model. Overall, these results suggest that 
sequential depletion against target negative mammalian cell monolayers will not confer the 
enrichment advantage to target specific binders that the model suggests. 
 
Figure 5-4. Sequential depletion of non-specific binders with mammalian cell 
monolayers. Mixtures of high-yield (A) or low-yield (B) CD276-specific, non-specific, 
and non-binding yeast were subjected to selection with 0, 2, 4, or 6 depletion steps 
followed by a single enrichment step. Average enrichment ratios are shown as the 
mean 3-9 trials. 
 
5.4.4 Depletion of Non-specific Binders by Blocking with Disadhered Mammalian Cells 
As an alternative to sequential depletion against mammalian cell monolayers, a pre-
blocking strategy using disadhered mammalian cells was employed (Figure 5-4). In this 
approach, yeast mixtures are incubated with disadhered target negative mammalian cells 
for 2 hrs prior to introduction of the whole mixture to a target positive mammalian cell 
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monolayer. Application of this scheme to the high-yield binder mixture conferred a 
considerable enrichment advantage to CD276-specific clone HS (120 ± 32) relative to non-
specific clone HN (12 ± 10), resulting in a 14 ± 6-fold selectivity in favor of clone HS 
(Figure 5-5A). This is a significantly higher selectivity (p=0.0002) than the 0 depletion 
scheme (0.7 ± 0.6), the current standard in the field. However, application of the same 
strategy to the low-yield mixture resulted in a weaker selectivity advantage of 7 ± 10 for 
CD276-specific clone LS relative to non-specific clone LN (Figure 5-5B). This selectivity 
is not definitively better than the 0 depletion case (0.2 ± 0.1, p=0.07). 
The results from the high-yield mixture are encouraging. The 14 ± 6-fold selectivity 
advantage for the CD276-specific binder relative to the non-specific binder will propagate 
through multiple rounds, accomplishing this study’s goal of non-specific binder depletion. 
The reduced ability to accomplish the same selectivity with the low-yield binder mixture 
is a surprising result. It does appear based on the 0 depletion data that the low-yield non-
specific binder does enrich more strongly against target positive cells than the low-yield 
CD276-specific binder. This could be the cause for the lack of selectivity, as any non-
specific binder that is not depleted by the pre-blocking strategy has a 6-fold higher 
enrichment ratio than the CD276-specific binder. 
The ability to strongly deplete the high-yield non-specific binders while being 
unable to deplete low-yield non-specific binders can still yield a functional improvement 
in selections from naïve libraries. It has been shown that strong- and mid-affinity binders 
can quickly out-enrich weaker binders in an EGFR-binding model system (Chapter 4). 
With the depletion of high-yield non-specific binders, the high- and mid-yield specific 
binders will have the opportunity to similarly out-enrich the remaining low-yield non-
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specific binders that could not be effectively depleted. Although the depletion of non-
specific binders will not be complete in this regime, it will confer an important incremental 
improvement for cellular selections using yeast surface display libraries. 
 
Figure 5-5. Depletion of non-specific binders with mammalian cell pre-blocking. 
Mixtures of high-yield (A) or low-yield (B) CD276-specific, non-specific, and non-
binding yeast were subjected to selection with or without mammalian cell pre-
blocking followed by a single enrichment step. Enrichment ratios are shown as the 
mean ± standard deviation of 6-12 trials.  
 
5.5. Conclusions 
In conclusion, the addition of depletion by pre-blocking with disadhered 
mammalian cells has the potential to improve the efficiency of yeast-displayed cellular 
selections by removing the highest yielding non-specific binding clones. Employment of 
this strategy yields a 14-fold enrichment advantage to a high-yield CD276-specific binder 
relative to a high-yield non-specific binder. This same advantage was not reflected with 
using low-yield analogues of this mixture. Sequential depletion with mammalian cell 
monolayers does not yield the expected result relative to mathematical models, suggesting 
there are non-specific losses of target-specific binders that are not specifically protein-
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protein interaction mediated. Alternatively, this result may stem from lower than expected 
yield of the non-specific binder against target negative cells, which would disfavor 
depletion as shown by the sensitivity analysis. Overall, these findings should increase the 
frequency of successful ligand selection campaigns using yeast-displayed cellular 
selections by removing the most problematic non-specific binders, allowing stronger 
target-specific binders the chance to dominate. 
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Chapter 6 – Concluding Remarks and Future Work 
Prior to the work presented in this dissertation, selection from yeast surface 
displayed ligand libraries on intact mammalian cells was a young technique with only six 
studies outside of this work utilizing similar selection strategies. This work builds on the 
foundations of cell-based ligand selection laid out by the Shusta lab by elevating 
enrichment of binders from dilute pools through the use of a new yeast surface display 
construct with an additional 40 amino acid linker that enhances the recovery of even 
micromolar binders, rigorously examining several enrichment strategies to determine the 
optimal protocol for ligand selection, developing a new technique for affinity selection 
against cellular targets, and probing techniques for depletion of non-specific binders from 
model pools. Together, these innovations comprise a full complement of techniques that 
can be (and in some cases, have been) immediately applied to ligand selection for a wide 
range of targets, including previously inaccessible targets such as GPCRs, ion channels, 
and multi-pass membrane proteins. However, many opportunities for innovation remain. 
The inability to robustly recover binders weaker than single digit nanomolar against 
cells with target expression on the order of 105 per cell (Chapter 2) limits the broad 
applicability of this technique. As it stands, transfectant cell lines with on the order of one 
million targets per cell need to be developed for most targets. While this is useful if the 
target of interest is known, this limits the ability to perform ligand-biomarker co-discovery 
experiments against poorly characterized cell lines or patient biopsy samples. Success in 
these areas would impart great diagnostic and proteomic utility on this technique. Our 
findings do suggest that lengthening the linker in the yeast surface display construct aids 
recovery even when target is limited, but no linker longer than 80 amino acids was tested 
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(Chapter 2). Current and future work involves further lengthening this linker by adding 20- 
or 40-mer segments of either a flexible alanine, serine, and proline rich linker or a rigid 
EAAAK alpha helical linker. The addition of a 40-mer alanine, serine, and proline rich 
linker to the original yeast surface display linker initially greatly improved performance in 
cellular selection, but the addition of further flexible length brings concerns of coiling that 
could yield a lower permutation length. The rigid alpha helical linker is expected to add 
additional length without this concern, building on the advantage conferred by increased 
linker length. 
Gaining a more fundamental understanding of the interaction between a yeast-
displayed ligand and a mammalian cell expressed receptor could help guide how to better 
design yeast-display constructs for this technique. The current understanding of this 
interaction is empirical and on a large scale. Briefly, higher expression levels of target on 
a per cell basis yield better recovery of yeast, and lengthening the yeast surface display 
linker further enhances this benefit for a sufficient (>6,000 ligands per cell) ligand display 
level. However, there is currently no molecular understanding of why this is the case. There 
are two potential hypotheses: 1) longer linkers increase the number of ligands that can 
physically reach and interact with their receptors, increasing avidity relative to yeast 
surface display systems with shorter linkers, or 2) longer linkers increase the effectiveness 
of each invidual ligand by better allowing it to navigate the multitude of molecules present 
on the cell surface to find the appropriate receptor. The first hypothesis arises from a spatial 
argument that only the ligands present on a small portion of the yeast cell can physically 
reach receptors present on the mammalian cell surface due to the curvature of the yeast cell 
and the short length of the linker relative to the scale of a yeast cell. Thus, increasing the 
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linker length improves binding by allowing better avidity by expanding the interacting area 
on a yeast cell, allowing more ligands to reach the mammalian cell surface. The second 
hypothesis is an accessibility argument, suggesting that a longer linker allows a ligand 
more freedom to access space on the cell surface and move past passive molecules that 
sterically hinder the ligand and receptor interacting with one another. Further TIRF or 
confocal microscopy studies could be employed to probe these hypotheses. A first level 
geometric approximation for the interacting area of a yeast cell can be made my assuming 
the yeast cell is a sphere that is physically contacting a mammalian cell that is approximated 
as a slab. The displayed ligands can simply be modeled as having a fully extended linker 
of known length, but it would be more rigorous to use computer simulations to determine 
the length of the most likely linker conformation. This knowledge is applied to the 
experiment by making yeast display ligands with different linker lengths with a constant 
number of ligands per interacting surface area. The ligands and receptors can then be 
fluorescently labeled and interactions observed by confocal or TIRF to measure the size of 
the interacting area and FRET to measure the total number of interactions. If the first 
hypothesis is correct, focus should be placed on increasing both the number of ligands per 
yeast cell and the interacting area, likely by adding rigid linker length. If the second 
hypothesis is correct, focus should be placed instead of making the most effective linkers 
for optimized receptor accessibility.  
With advances in deep sequencing technology, the question of what motifs are 
present in target-specific ligands is being answered32. Selections for these ligands are 
generally carried out using soluble targets, meaning the binders surveyed interact with the 
epitopes presented by soluble targets, which are not necessarily the same as those of their 
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cellularly expressed counterparts. Although the current dataset is too small to draw any 
conclusion, translatable fibronectin domain and affibody clones selected against soluble 
Thy1 and CD276 did not show sequence overlap with clones selected against target 
expressing cells (Chapter 3). Interestingly, even affibody clones sorted against soluble 
CD276 only and against soluble CD276 followed by CD276-expressing cells did not 
overlap despite being isolated from the same starting point. This could potentially mean 
that the motifs that arise in clones that bind soluble target are different from those that arise 
when binding the same cellular target. With advances in depletion, it would be possible to 
sort naïve libraries against soluble and cellular target side-by-side to yield enriched pools 
of binders to each without fear of obtaining a high frequency of non-specific binders. Deep 
sequencing these pools would answer the question of if new motifs arise, helping to inform 
the design of new ligand libraries. 
Building from this idea, there is diminishingly little knowledge of what motifs are 
present in non-specific binding ligands. Cellular selections can be applied to answer this 
question. Naïve libraries would be subjected to enrichment against several different 
mammalian cell types in series, yielding binders that are cell dependent rather than 
biomarker dependent. Deep sequencing these pools would yield sequence information of 
what motifs arise. Given enough sequence information, the next generation of libraries 
could be built clone-by-clone to contain diminishingly few non-specific binders, yielding 
more efficient selections with little fear of enriching these non-specific clones. 
 In total, the work presented in this dissertation builds a body of techniques that can 
be utilized for both fundamental protein engineering and applied ligand selection. Further 
studies into the yeast-displayed cellular selection system on the molecular level can aid our 
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understanding of yeast-mammalian cell interactions and inform further redesign of the 
yeast surface display construct. Cellular selections can also be applied to gain fundamental 
knowledge of what a binder looks like, whether that binder is target specific or not. 
However, the largest impact of this system can be made immediately by utilizing these 
tools to help close the gap between proteomics and ligand engineering.  
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Appendix A – Phage Display of Fibronectin Domains for 
Cellular Selection of Ligands 
Ligand selections against mammalian cell monolayers yield binders that are 
conditioned to bind the full length cellular target of interest. However, the best method to 
conduct these selections may not yet have been optimized. This thesis demonstrates 
optimization and successful application of cellular selections with yeast surface display. 
Other groups have employed phage display8 for cellular selections with success47. Phage 
have potential advantages for selection in this realm over yeast due to their small size. At 
their scale, phage are subject to much less shear associated with washing than yeast, 
theoretically allowing for fewer specific interactions to be broken by shear. Phage also 
require much less avidity to bind, potentially allowing for discovery of binders to targets 
with lower expression than one million/cell. 
Phage display work with fibronectin domains was completed using a phagemid 
system. This phagemid was a kind gift from Professor Andreas Pluckthun (University of 
Zurich, Zurich, Canton of Zurich, Switzerland). In its obtained form, the pAK100 
plasmid114 encodes for a fusion of the gene of interest (cloned between two asymmetric 
SfiI restriction sites), a MYC tag, and a truncated form of minor phage coat protein pIII. 
Several modifications were made to this vector by gene construction and ligation. NheI 
and BamHI restriction sites were introduced between the two SfiI sites for facile gene 
shuttling from pCT and pET vectors maintained in house. The pelB leader sequence for 
cytoplasmic protein production followed by shuttling to the periplasmic space was 
removed and replaced by a DsbA leader sequence, which transports proteins to the 
periplasmic space co-translationally115. These changes constitute the pAKDM vector, 
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which yields phage that express either zero or one ligand on pIII (). Additional 
modifications to the vector introduce a GCN4 leucine zipper and antibody hinge between 
the ligand and the truncated pIII to allow for bivalent, antibody-like display for increased 
avidity116. These insertions constitute the pAKDB vector (). 
 
Figure 7-1. Schematic of phage display constructs. (A) The pAKDM vector encodes for 
a fusion protein that contains a protein of interest (POI), a flexible linker, a MYC tag, 
an amber stop codon, and a truncated pIII. (B) The pAKDB vector encodes for a 
fusion protein of the protein of interest, a flexible linker, an antibody hinge, a GCN4 
leucine zipper, a MYC tag, an amber stop codon, and a truncated pIII. The leucine 
zipper and antibody hinge dimerize with other fusion constructs, which either do or 
do not have the truncated pIII due to imperfect amber suppression. 
Phage were grown and propagated using standard published protocols, with helper 
phage (New England Biolabs) used for phage production. Phage were recovered by 
standard PEG/NaCl precipitation. Titer was determined by infection into XL1-Blue 
(Agilent) E. coli and dilution plating on 2XYT plates supplemented with 25 mg/L 
chloramphenicol. 
Initial phage selection experiments were carried out using mixtures of phage 
displaying fibronectin E6.2.6’33 with either plasmid-free helper phage or phage displaying 
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fibronectin clone WT’76 in pAKM or pAKDM plasmid modified to replace the 
chloramphenicol resistance marker with an ampicillin resistance marker. Selections were 
carried out against disadhered A431 cells due to their high EGFR expression 
(2.4x106/cell33). Dilution plating of sorted pools yielded minimal enrichment (data not 
shown), and difficulty was observed in dilution plating relating to loss of infectability of 
XL1-Blue depending on the age of the maintained plate. To mitigate this difficulty, 
quantification with qPCR was adopted. Phage were either transfected into XL1-Blue and 
miniprepped immediately, or directly prepped by breaking the phage coat with buffer WN 
and applying the lysate to a miniprep column. Primers for specific identification of the 
E6.2.6’ family of molecules or clone WT’ were used33. 
In an effort to decrease non-specific recovery of phage, experiments were carried 
out using multiple binding buffers (Figure 7-2). The standard binding buffer for phage 
display selection, PBSA + 0.02% Tween-20 (a detergent meant to break non-specific 
hydrophobic interactions), was compared to serum free DMEM and 2% milk PBS. The 
enrichment in each of these buffers was essentially not different (Figure 7-2A), but the 
enrichment ratios are also quite weak. The yields echo this result, but it was concerning for 
the overall applicability of the method that the strongest binder recovery was 0.3 ± 0.1% 
for E6.2.6’ with PBSA + 0.02% Tween-20 (Figure 7-2B). These yields and enrichment 
ratios would require heavier over-sampling of a library and many additional rounds of 
selection to make an enriched pool of binders than yeast display methods discussed earlier 
in this work. 
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Figure 7-2. Effect of binding buffer composition on phage recovery in an EGFR-
expressing system. Phage displaying monovalent E6.2.6’ and monovalent WT’ were 
mixed in a 1:1,000 ratio and selected against A431 cells in either PBSA + 0.02% 
Tween-20, DMEM (serum free), or 2% milk PBS. Enrichment of E6.2.6’ (A) and yield 
of both clones (B) are shown as mean ± range of two trials. 
Despite the discouraging results reported, additional experiments were carried out 
to determine the effect of differing EGFR expression level on the ability to effectively sort 
EGFR-binding fibronectin domains in both pAKDM and pAKDB vectors (Figure 7-3). 
These data for clones binding MDA-MB-468 (1.5x106 EGFR/cell33) and MDA-MB-231 
(1.9x105 EGFR/cell33) generally show much stronger enrichment of binding clones relative 
to earlier experiments while maintaining the sub-1% recovery regardless of affinity. This 
suggests that MDA-MB-468 and MDA-MB-231 cells may retain fewer non-specific 
binding interactions than A431 cells. However, the high enrichment and unrealistic yield 
against MCF-7 (1.2x102 EGFR/cell33) call these results into question. 
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Figure 7-3. Effect of EGFR expression on the selection of EGFR-binding fibronectin 
domains in monovalent or bivalent phage vector. Phage displaying monovalent or 
bivalent E6.2.6’ or E6.2.6’ N78S and monovalent or bivalent WT’ were mixed in a 
1:1,000 ratio and selected against MDA-MB-468, MDA-MB-231, or MCF-7 cells in 
either PBSA + 0.02% Tween-20. Enrichment (A) and yield (B) of binders are shown 
as mean ± standard deviation of three trials. pAKDB E6.2.6’ was not selected against 
MDA-MB-468. This is denoted by an X. 
Rather than attempt to experimentally improve the yield of binding clones or 
investigate the MCF-7 binding results further, a simple modeling approach was employed 
to interrogate the generally weak performance of this system. The transient binding 
equation (Equation 1) was solved in MATLAB while varying multiple parameters, 
including phage display fraction (the fraction of phage that express a ligand), the number 
of cells input into the selection, and the number of phage input into the selection (at a 
constant 1:10,000 binder:non-binder ratio) (Figure 7-4). In both cases of 0.1%, binding 
phage cannot be effectively enriched (maximum enrichment ratio = 1.45) (Figure 7-4A,C). 
For a 70 nM binder with a display fraction of 10%, 10-fold enrichment is observed when 
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1x106 cells are introduced into the system (Figure 7-4B); a high concentration of receptor 
is required in the system to yield sufficient enrichment. A 0.2 nM binder with a display 
fraction of 10% shows 50-fold enrichment with 1x104 cells in the system, with enrichment 
improving as additional cells are added (Figure 7-4D). Based on these data, it appears likely 
that display fraction could be problematic, with early experimental results mirroring the 
low display fraction cases. Thus, these data motivated determining the display fraction of 
phage pools and, if possible, optimizing the display fraction to yield more efficient 
selection. 
𝑑𝐶
𝑑𝑡
= 𝑘𝑓[𝑅𝑇 − 𝐶] [𝐿0 − (
𝑛
𝑁𝐴𝑉
) 𝐶] − 𝑘𝑟𝐶                              (1) 
C = Number of ligand/receptor complexes (#/cell) 
t = Time (s) 
kf = Association rate constant (M-1s-1) 
RT = Number of receptors present on the cell surface (#/cell) 
L0 = Number of ligands initially present (M) 
n = Concentration of cells present (cells/L) 
kr = Dissociation rate constant (s-1) 
NAV = Avogadro’s number (6.02x1023 #/mole) 
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Figure 7-4. Modeling of phage displaying ligands binding cells with high target 
expression. Phage selections were modeled in MATLAB assuming transient binding 
mimicking the standard 2 hour selection process. The volume for selection was not 
varied from 100 μL. Cell input and phage input were varied to observe the effect on 
the enrichment of specific binders from the overall pool. The yield of non-binders was 
assumed to be 0.1% of the input based on previous experiments. A 70 nM affinity 
with display fraction of 0.1% (A) or 10% (B) and a 0.2 nM affinity with display 
fraction of 0.1% (C) or 10% (D) are shown. 
To determine the display fractions of phage pools, western blot analysis was 
conducted using the MYC tag between the fibronectin domain of interest and the truncated 
pIII. For all analysis, it was assumed that either zero or one pIII fusion are incorporated per 
phage particle. Phage pools of E6.2.6’, E6.2.6’ N78S, and WT’ were produced with seven 
different sets of conditions: room temperature phage production, 30°C phage production 
(baseline condition), 37°C phage production, addition of helper phage 30 min after IPTG 
addition, addition of helper phage 30 min before IPTG addition, decreased IPTG 
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concentration, and with the addition of 1% dextrose to the 2XYT media (Figure 7-6 and 
Figure 7-7). Phage titers were quantified by dilution plating, and equal amounts were added 
to each well. Membranes were stained with mouse anti-MYC clone 9E10 (BioLegend) 
followed by goat anti-mouse HRP (Abcam). Luminescence was recorded using a 
ChemiDoc (Bio-Rad), and relative luminescence was quantified by Image Lab software. 
 
Figure 7-5. Molecular weights of phage constructs analyzed by western blot. 
 
 
Figure 7-6. Western blot analysis of fibronectin clone WT’ in pAKDM and pAKDB 
vectors. Phage displaying fibronectin clone WT’ were produced under seven different 
conditions, as noted. Lane 1 contains a prestained protein ladder (Bio-Rad). Lanes 2-
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8 contain monovalent phage (A). Lanes 9-15 contain bivalent phage (B). Relative 
luminescence was quantified using Image Lab software. 
 
Figure 7-7. Western blot analysis of fibronectin clone E6.2.6’ in pAKDM and pAKDB 
vectors. Phage displaying fibronectin clone E6.2.6’ were produced under seven 
different conditions, as noted. Lane 1 contains a prestained protein ladder (Bio-Rad). 
Lanes 2-8 contain monovalent phage. Lanes 9-15 contain bivalent phage. Relative 
luminescence was quantified using Image Lab software. 
This analysis seems to show the root of the problem with the current system. In 
many instances, it does not appear that displaying phage were produced at all. The addition 
of dextrose to the 2XYT broth appears to be inhibitory to protein production as there is 
lower signal in many cases relative to the baseline condition. Overall, no change in 
production condition drastically increased the amount of display observed, and there was 
no consensus condition that was universally helpful for all clones and display architectures. 
In an effort to understand the absolute display fraction of phage, the strongest 
producing phage pools were compared to a 3xMYC-GST fusion protein (Proteintech) by 
western blot (Figure 7-8). Unfortunately, there was either an error in the quantification of 
the 3xMYC-GST fusion protein, or of the phage pools because the percentages of phage 
displaying appear to be over 100% in almost all cases. At this point, a pET WT’-MYC-
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His6 protein was designed to replace the 3xMYC-GST fusion protein in the analysis, but it 
was never produced. The yeast surface display portion of the project began producing 
interesting results at this time, and the phage display efforts were never revisited. 
 
Figure 7-8. Western blot analysis of fibronectin domains for absolute quantification. 
Phage displaying fibronectin clone E6.2.6’, E6.2.6’ N78S, or WT’ were produced and 
western blotted with a 3xMYC-GST fusion protein for absolute quantification (A). 
Relative luminescence was quantified using Image Lab software. The percentage of 
displaying phage is reported as one trial, or two trials with mean ± range (B). 
As previously discussed, phage display methods can be successfully employed for 
cellular selections. Previous work as shown success using scFvs and short peptides in 
phagemid vectors47. Additionally, other protein scaffolds, including fibronectin domains12, 
affibodies11, and DARPins115 have been successfully phage displayed and selected against 
soluble targets. The display fractions of these scaffolds have previously been optimized 
such that display fraction is high enough for suitable selection. Thus, enrichment issues 
suggested by modeling efforts are not a major problem; clones with at least monovalent 
display and sufficient affinity can be recovered with reasonable enrichment. In order for 
this work to have had the same success, display fraction would have needed to be further 
optimized. This could be done in many ways. Stabilization of the fibronectin-pIII fusion 
protein could allow for better production of fusions and thus better display overall. 
Additional efforts could be made to optimize the protein production conditions for each 
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clone to yield better display. Phage vector systems could also be employed for phage 
display. In these systems, the entire phage genome is encoded in a large plasmid rather than 
just the ligand-pIII fusion that’s encoded in a phagemid. Thus, every copy of pIII that is 
produced is a pIII fusion and must be incorporated to have viable, infective phage. This 
yields phage that display three to five copies of the fusion unless no pIII are incorporated 
into the phage coat. Thus, display fraction should theoretically be near 100%, and the phage 
will have the advantage of a small amount of avidity to allow for the recovery of weaker 
interactions. This approach has been applied using phage displayed scFvs for discovery of 
binders to blood-brain barrier proteins in past work49. Anecdotally, phage vectors are 
harder to work with than phagemid vectors because of their large size, but the benefit of 
high display fraction and avidity would likely lead to successful selections. 
